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1. Introduction 
1.1. Regulation of the mammalian cell cycle 
Cell growth and cell division are fundamental events of cell behavior in all 
organisms. There are two main events or states during the cell cycle that consist of 
interphase and mitosis including cytokinesis. Proper division of the eukaryotic cell 
depends on two main processes, first, the high fidelity and faithful copying of its 
genome and second, equal distribution of the duplicated genome and cell material 
into the daughter cells.  
 
Figure 1.1 Mammalian cell cycle and its control. The cell cycle is divided into four phases; G1 
(GAP1), S (DNA synthesis), G2 (GAP2) and M (Mitosis) phase. The progression through the cell cycle 
is regulated by complexes containing a cyclin and a cyclin-dependent kinase. CcnD interacts with 
Cdk4 and Cdk6 and the cell enters the cell cycle. CcnE-Cdk2 complex is important for G1-S transition, 
CcnA-Cdk2 directs the progression through S-phase and CcnA-Cdk1 leads the cell through G2 
restriction point. Finally, CcnB-Cdk1 trigger mitosis (Malumbres and Barbacid, 2005). 
Within interphase there are two control points called G1 (GAP1) and G2 
(GAP2) phase which control the transition from one phase to the next. G1 controls 
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entry into synthesis phase (S-phase) and entry into Mitosis (M-phase) is safeguarded 
by G2 (Figure 1.1). The cell cycle starts with cell growth and preparation of the 
chromosomes for replication, followed by synthesis of DNA and duplication of the 
centrosome, then providing that replication was correct finally undergoes mitosis 
(Norbury and Nurse, 1992). The time required for completion of one eukaryotic cell 
cycle is highly variable and cell type specific. The most crucial decision of the cell is 
whether to continue another round of cell division or to exit the cell cycle and enter a 
quiescent state known as G0 (G zero). Most cells in an adult organism including 
hepatocytes are quiescent in order to carry out their main functions such as 
secretion, storage or metabolism of compounds. Only specialized cells maintain 
active proliferation, such as those found in the hematopoietic system and the gut 
epithelium.  
The cell cycle machinery is usually activated by the presence of mitogen 
factors leading to induction of the initiators of the cell cycle, the family of D-type 
cyclins. The D-type cyclins preferentially bind to and activate Cdk4/Cdk6. These 
complexes then phosphorylate and partially inactivate members of retinoblastoma 
pocket proteins (Rb, p107, p130) (Bartek et al., 1996; Harbour et al., 1999; Sherr, 
1996). Phosphorylation of Rb, a transcriptional repressor, leads to the release of the 
transcription factor family E2Fs resulting in the induction of E-type cyclins which then 
bind and activate Cdk2. CcnE-Cdk2 complexes phosphorylate additional proteins 
such as NPM and CP110 involved in centrosome duplication, Cdt1 involved in DNA 
synthesis,  and perpetuates the cell cycle. This positive feedback loop generates a 
rapid rise in E2F-dependent transcription and leads to the onset of S-phase. This 
restriction point is a stage where cells no longer require mitogen signals. CcnE-Cdk2 
activity is thought to be essential for the initiation of DNA replication (Dannenberg et 
al., 2000; Ezhevsky et al., 2001; Hwang and Clurman, 2005; Lauper et al., 1998; 
Lundberg and Weinberg, 1998; Sage et al., 2000). A-type cyclins accumulate 
throughout S-phase. Cdk2 kinase also binds CcnA and the formation of this complex 
plays a role in progression through DNA synthesis and passing through the G2 
phase. At the end of interphase, CcnA activates Cdk1 to facilitate the onset of 
mitosis. After nuclear envelope breakdown, A-type cyclins are degraded, enabling 
the formation of CcnB-Cdk1 complexes. B-type cyclins in association with Cdk1 are 
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essential for triggering mitosis (Figure 1.1) (Edgar et al., 1994a; Edgar et al., 1994b; 
Malumbres and Barbacid, 2005; Nigg, 1995).  
The Anaphase-Promoting Complex (APC), also known as cyclosome, is a 
large multi-subunit complex that acts as an E3 enzyme to catalyse the transfer of 
ubiquitin to various mitotic substrates, including cyclins and controls the exit from 
mitosis. APC activity is high in G1 and then declines upon the appearance of G1 
cyclins (Peters et al., 1996).  
 
1.2. To regulate and be regulated: Cyclin - Cdk  
The phases of the cell cycle are precisely coordinated and follow in a well-
orchestrated and systematic order to assure proper DNA duplication and cell division. 
The supervisors of the cell cycle are the cyclin-dependent kinases (Cdks), a group of 
serine/threonine kinases that form active heterodimer complexes upon binding to 
cyclins. Cyclins are regulatory subunits that are expressed in a cyclical manner 
throughout the cell cycle; as such they are produced and degraded as needed 
(Morgan, 1997; Sherr, 2000).  
Cdks are defined as protein kinase catalytic subunits that are closely related to 
the prototypical Cdc2 in Saccharomyces cerevisiae and Cdc28 in 
Schizosaccharomyces pombe (Nasmyth, 1996; Stern and Nurse, 1996). However, 
complete activation of Cdk requires more than just cyclin binding. The Cdk subunit 
must be phosphorylated by kinases referred to as Cdk-activating kinase (CAK) 
(Fisher and Morgan, 1994). Human Cdk1-CcnB, Cdk2-CcnA or Cdk2-CcnE 
complexes interact with high affinity in the absence of other components or 
modifications (Desai et al., 1995). Some complexes, such as Cdk1-CcnA and Cdk7-
CcnH do not bind tightly unless the Cdk subunit is phosphorylated at the activating 
threonine residue (Desai et al., 1995; Ducommun et al., 1991; Fisher et al., 1995). 
Cyclins are defined as proteins with structural homology to prototypical cyclins 
described in yeast and possess the ability to activate a Cdk catalytic subunit. Cyclins 
share a sequence motif known as the cyclin box, a 100 amino acid section with a 
high sequence homology amongst all known cyclins, which is necessary for Cdk 
binding and activation (Kobayashi et al., 1992; Lees and Harlow, 1993). There are 
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several types of cyclins that are active during different parts of the cell cycle, which 
leads the phosphorylation of various substrates by Cdk. In addition, there are also 
several "orphan" cyclins for which no Cdk partner has been identified yet (Malumbres 
and Barbacid, 2005; Morgan, 1997). 
Some cyclins and Cdks are not only regulating the cell cycle, but are also 
involved in the regulation of transcription and mRNA processing. In higher 
eukaryotes CAK is a Cdk complex containing Cdk7-CcnH (Nigg, 1996). Some of the 
Cdk7-CcnH complexes found in humans are associated with transcription factor 
TFIIH, where it may act as a kinase that phosphorylates the C-terminal domain (CTD) 
of RNA polymerase II during transcription (Svejstrup et al., 1996; Tassan et al., 
1995). Cdk8-CcnC also associates with RNA polymerase II and phosphorylates CDT 
(Leclerc and Leopold, 1996; Leclerc et al., 1996; Rickert et al., 1996; Tassan et al., 
1995). Cdk9 was found to be a component of the complex TAK/P-TEFb, an 
elongation factor for RNA polymerase II-directed transcription, and phosphorylates 
CDT of the largest subunit of RNA polymerase II. The Cdk9 kinase forms a complex 
with CcnT or CcnK (Cabart et al., 2004; Fu et al., 1999; Peng et al., 1998). CcnD1 
binds RAD51 and BRCA2 proteins and promotes homologous recombination 
mediated DNA repair independently of Cdk4/6 activity (Jirawatnotai et al., 2011; Li et 
al., 2010). 
 
1.2.1. Regulation and structural properties of Cdk2 and E-type cyclins 
Cyclin-dependent kinase 2 (Cdk2) is a Ser/Thr protein kinase with a molecular 
weight of 34 kDa. It is an important component of the cell cycle machinery; its kinase 
activity is regulated by association with a cyclin subunit and is found mainly in the 
nucleus (Elledge and Spottswood, 1991; Koff et al., 1991; Satyanarayana et al., 
2008). Main activating cyclins are E-type and A-type cyclins (Koff et al., 1992; Tsai et 
al., 1991), which possess a nuclear localization signal (NLS), so Cdk2 depends on 
cyclin for its nuclear translocation (Diehl and Sherr, 1997).  Typical substrates of 
Cdk2-CcnE kinase are involved in histone modification, DNA replication, DNA repair 
and centrosome duplication. Cdk2-CcnA substrates include proteins important for 
exit of S-phase, but also proteins involved in DNA replication, DNA repair, histone 
modification and cell cycle checkpoints (Chi et al., 2008; Higashi et al., 1995). 
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Interestingly, it has been shown in mammals that inhibition or deletion of Cdk2 is 
dispensable for cell proliferation and this is likely due to compensation of other 
kinases (Kaldis and Aleem, 2005). For example, Cdk1, which was found to be 
essential for cell cycle, can take over the functions for all interphase Cdks (Cdk2, 
Cdk4 and Cdk6) in mouse embryos untill midgestation in the case of their genetic 
inactivation (Santamaria et al., 2007). 
CcnE1, historically referred to as CcnE, was first identified by its ability to 
compensate for the proliferative defects found in cyclin-deficient yeast cells (Koff et 
al., 1991; Lew et al., 1991). A second member of the family, termed CcnE2, was 
discovered recently, shares a 47% overall amino-acid homology with CcnE1, and is 
70% homologous with the cyclin box (Gudas et al., 1999; Lauper et al., 1998; 
Zariwala et al., 1998). Although specific studies on CcnE2 are limited, the two CcnE 
family members were thought to exhibit similar activities based on high homology. 
Nevertheless, there is increasing evidence for differential and nonredundant 
functions of both E-cyclins (Caldon and Musgrove, 2010).  
The mammalian CcnE gene encodes for several polypeptides with molecular 
weights ranging from 39 to 52 kDa. The main CcnE protein contains a cyclin box 
domain for recognition of substrates or inhibitors, a substrate recognition motif 
(VxCxE) that binds Rb protein (Kelly et al., 1998) and a PEST domain that is 
responsible for targeting CcnE for degradation (Rechsteiner and Rogers, 1996; 
Rogers and Rechsteiner, 1986).  
CcnE1 is required for entry into S-phase and has a cyclical expression, 
peaking at the G1-S transition and then decaying as S-phase progresses. CcnE1-
Cdk2 activity is highest in G1-S cells and lowest in quiescent cells (Dulic et al., 1992; 
Ekholm et al., 2001; Koff et al., 1992). The amount of CcnE1 available was thought to 
be the limiting factor for the progression through G1 phase (Dulic et al., 1992; 
Jackson et al., 1995; Koff et al., 1991; Koff et al., 1992; Lew et al., 1991; Morgan, 
1996; Ohtsubo et al., 1995; Planas-Silva and Weinberg, 1997; Rempel et al., 1995; 
Resnitzky and Reed, 1995; Resnitzky et al., 1994). 
Transcriptional control of the E-type cyclins is mediated by E2F transcription 
factors, which are activated via release from Rb following hyperphosphorylation 
during late G1 (Bartek et al., 1997; Sherr and McCormick, 2002). E2F is a 
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transcription factor that regulates the expression of many different genes involved in 
S-phase (DeGregori et al., 1995; Ohtani et al., 1995; Weinberg, 1996). CcnE1 itself is 
an E2F target gene and the CcnE1 promoter has been shown to contain defined E2F 
binding sites (Figure 1.2) (Geng et al., 1996; Le Cam et al., 1999; Ohtani et al., 
1995). 
 
 
Figure 1.2 The basic regulatory mechanism of the CcnE-Cdk2 complex. In order to pass through 
the G1 restriction point, phosphorylation of the transcriptional repressor Rb by the CcnE-Cdk2 complex 
must occur. (A) The repressor Rb binds to transcriptional start sites and inhibits E2F and gene 
transcription of other target genes; (B) CcnE-Cdk2 hyperphosphorylates and thus inactivates Rb and 
(C) transcription of S-phase genes starts. 
 
CcnE is an unstable protein that is degraded by two distinct pathways both 
involving the ubiquitin-proteasome system. The accessibility of CcnE to these 
proteolytic pathways depends upon whether CcnE is monomeric or bound to Cdk2. 
Monomeric CcnE is exceptionally labile and degraded by cullin-3 (Cul-3), a 
scaffolding protein for ubiquitin ligases (E3). When CcnE is in complex with Cdk2 a 
second pathway of CcnE degradation involving the SCF-Fbw7 ubiquitin ligase is 
utilized. This interaction between Fbw7 and CcnE requires CcnE-Cdk kinase activity 
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and autophosphorylations (Clurman et al., 1996; Koepp et al., 2001; Singer et al., 
1999; Won and Reed, 1996). 
E-type cyclins primarily activate Cdk2, but they can also interact with Cdk1 in 
some cell types once Cdk2 is genetically inactivated (Dulic et al., 1992; Koff et al., 
1992). In a Cdk2-independent manner, CcnE associates with DNA near replication 
origins, and facilitates loading of MCM (minichromosome maintenance) through 
direct interaction with MCM2-7 complex and Cdt1, a component of the origin 
recognition complex (ORC) in order to initiate G0 to S-phase progression (Geng et 
al., 2007). 
 
1.3. Supervising the supervisor - CKIs 
The activity of many Cdk-Ccn complexes is controlled by Cdk-inhibitors (CKIs) 
that are assigned to one of two families based on their structures and Cdk targets 
(Table 1.1). The Cip/Kip (CDK interacting protein/Kinase inhibitory protein) and Ink4 
(Inhibitor of Kinase 4) gene families provide a tissue-specific mechanism by which 
cell cycle progression can be restrained in response to extracellular and intracellular 
signals (Harper et al., 1995). 
 
Table 1.1 CKI families and their members 
Family Members: Encoded by: 
Cip/Kip  family 
p21 Cip1 Waf1 Cdkn1a 
p27 Kip1 Cdkn1b 
p57 Kip2 Cdkn1c 
Ink4 family 
p15 Ink4b Cdkn2b 
p16 Ink4a Cdkn2a 
p18 Ink4c Cdkn2c 
p19 Ink4d  Cdkn2d  
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 The Cip/Kip family includes p21Cip1, p27Kip1, and p57Kip2, all of which contain 
characteristic motifs within their amino-terminal moieties that enable them to bind to 
G1 specific cyclin and Cdk subunits, rendering them inactive and thereby preventing 
further progression of the cell cycle (Besson et al., 2008; Nakayama, 1998). This is 
accomplished via domains at the N-terminus of p21 and p27 which are required for 
cyclin and Cdk binding (Ball and Lane, 1996; Chen et al., 1996; Fotedar et al., 1996).  
Sequences similar to the cyclin-binding motifs found in p21 and p27 are also 
present in the transcription factor E2F and the pRb-related protein p107 (Adams et 
al., 1996; Shiyanov et al., 1996; Zhu et al., 1995). The Ink4 (inhibitors of CDK4) 
family contains four members p15Ink4b, p16Ink4a, p18Ink4c, and p19Ink4d, all of which 
have the ability to specifically inhibit Cdk4/6 (Ortega et al., 2002; Roussel, 1999). 
CKIs of the Cip/Kip family were all initially thought to predominantly inhibit the 
activities of CcnD-, CcnE-, and CcnA-dependent kinases. However, recent studies 
revealed that they also might promote activation of CcnD–Cdk4/6 complexes by 
directing it to the cell nucleus and by increasing the stability of the D-type cyclins 
(Cheng et al., 1999; Harper et al., 1995; LaBaer et al., 1997; Soos et al., 1996; 
Zhang et al., 1994).  
p21 is a well-known tumor suppressor and its loss is a hallmark of many 
cancers, including hepatocellular carcinoma (Hui et al., 2008). Mammalian p21 
appears to be controlled primarily at the transcriptional level by p53, a transcriptional 
regulator mediating the cell cycle arrest that occurs after DNA damage (Harper and 
Elledge, 1996). Under various conditions, p21 accumulation leads to growth arrest, 
differentiation or cellular senescence. Phosphorylation of the p21 protein affects its 
stabilization and localisation. Phosphorylation by CcnE-Cdk2 promotes its binding to 
SKP2 (S-phase kinase associated protein 2) leading to its ubiquitination and 
subsequent proteolysis; while other phosphorylations can lead to nuclear exclusion 
thereby promoting antiapoptotic functions and/or its degradation (Abbas and Dutta, 
2009). 
p27 is a potential tumor suppressor and a prognostic indicator since its 
decreased or absent expression is observed in various types of human cancers with 
poor prognosis including HCCs (Lee and Kim, 2009; Matsuda, 2008). However, 
some controversial data also indicate additional roles for promoting tumor growth 
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depending on the cellular localization (Abukhdeir and Park, 2008).  It is constitutively 
expressed in quiescent cells, for example liver cells, but downregulated during liver 
regeneration (Kossatz et al., 2004). p27 is regulated primarily at the posttranslational 
level by several mechanisms. Part of its regulation is mediated via CcnE-Cdk2 
dependent phosphorylation at the Thr187 which directs p27 to cytoplasm and 
subsequent proteasomal degradation mediated by SCFSKP2 (Skp-Cullin-F-box) E3 
ubiquitin ligase complex (Vervoorts and Luscher, 2008). 
 
1.4. Tumor suppressor p53: a role in cell cycle regulation 
p53 is a transcription factor encoded by the TP53 gene that regulates the cell 
cycle and modulates cellular responses against potentially tumorigenic events, and is 
therefore described as a tumor suppressor. p53 is involved in a broad repertoire of 
cellular functions like cell metabolism, stem cell renewal, autophagy, oxidative status, 
etc. (Brady and Attardi, 2010). In response to stimuli that activate p53, cells can 
undergo either apoptosis or cell cycle arrest. Apoptosis induced by the transcriptional 
activity of p53 occurs by activating target genes such as Bax, Noxa, PUMA and 
PTEN or by interaction with Bcl-2 family of proteins via translocation of p53 to the 
mitochondria (Pietsch et al., 2008). The p53 protein can interfere with cell cycle 
progression by direct or indirect repression of cell cycle regulators (Bohlig and 
Rother, 2011).  
In cell homeostasis, p53 is rapidly bound by MDM2, a RING finger E3 ligase 
that promotes the polyubiquination and proteasomal degradation of p53. The tumor 
suppressor p53 becomes activated in response to various stress signals, such as 
those from kinases ATM and ATR which lead to the phosphorylation of p53. The 
main posttranslational modifications that stabilize p53 are numerous 
phosphorylations and acetylations which inhibit the binding of MDM2 and its 
subsequent degradation. The p53 pathway is of critical importance in mediating 
innate tumor suppression in cells that have sustained genetic deviations that drive 
tumor initiation and progression (Meek, 2009; Meek and Anderson, 2009). 
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1.5. Consequences of CcnE-Cdk2 ablation in vivo 
Before CcnE1, CcnE2 or Cdk2 knockout mice were generated, the general 
opinion was that CcnE-Cdk2 complex was the master regulator of the G1-S transition 
and that CcnE1 executes its cell cycle functions via Cdk2-dependent phosphorylation 
of its substrates. Surprisingly, single knockouts of CcnE1, CcnE2 or Cdk2 develop 
mainly normally, although defects in meiosis were evident in the CcnE2 and Cdk2 
knockout mice (Berthet et al., 2003; Geng et al., 2003; Ortega et al., 2003; Parisi et 
al., 2003). However, CcnE1 and CcnE2 double knockout mice are embryonic lethal, 
although this was not cell cycle dependent but rather due to impaired endoreplication 
of trophoblast giant cells and megakaryocytes. CcnE1-/-CcnE2-/- mouse embryonic 
fibroblasts (MEFs) proliferate, but have a defect in exit from G0. Double CcnE-
deficient MEFs also show resistance to transformation with oncogene pairs H-Ras/c-
Myc, H-Ras/p53DN or H-Ras/ E1A. These results revealed that E-type cyclins are 
dispensable for continuously cycling cells but suggest a requirement for cell cycle 
reentry from quiescence and oncogenic transformation (Geng et al., 2003). A recent 
regeneration study using a model of partial hepatectomy (PH) revealed that single 
deletion of CcnE1 or CcnE2 does not prevent quiescent hepatocytes from entering 
the cell cycle; however, CcnE1 seems to be important for endoreplication and 
polyploidy in hepatocytes (Nevzorova et al., 2009). 
The results from these studies initiated some speculations about the function 
of E-cyclins. First of all, neither CcnE nor Cdk2 are essential for cell division; 
secondly, CcnE1 is required for endoreplication; thirdly, CcnE1 is required for 
oncogenic transformation; and finally, CcnE2 and Cdk2 are required for meiosis. 
 
1.6. The biology of hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is a primary cancer of the liver and it is 
among the five most frequent cancers in the world (WHO-World Health Organization 
2011). Mortality from liver cancer is very high and increasing during last two decades 
in comparison to other malignancies and therapy options are limited due to late 
diagnosis. The major risk factor for the development of HCC is chronic liver injury 
resulting from hepatitis infection, alcohol abuse or exposure to aflatoxin B1 (Jemal et 
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al., 2009; Lee et al., 2004; Llovet et al., 2003). More recently, obesity is a worldwide 
rising problem and a risk for a range of human diseases; growing evidence suggests 
that fatty liver (NAFLD – nonalcoholic fatty liver disease, NASH - nonalcoholic 
steatohepatitis)  increases the risk for HCC  (Starley et al., 2010). Besides chronic 
liver damage, additional risk factors are dietary exposure to carcinogens, 
environmental pollutants and cigarette smoke shown to induce liver cancer in 
experimental animals (Bosch and Munoz, 1988; Bosch et al., 2004). Due to the 
climbing mortality rates associated with HCC new and more effective therapies are 
required and are the focus of much attention in research. Recently, progress has 
been made in clinical trials with Sorafenib, a multikinase inhibitor (inhibits BRAF, 
VEGFR, PDGFR). This therapeutic approach is now standard care for patients with 
advanced stages of HCC. However, the need for new specific therapies still exists. 
Therefore, more than 50 chemicals are currently being tested for use in the treatment 
of HCC (Villanueva and Llovet). 
 
1.7. CcnE and cancer 
CcnE1 expression has been extensively studied in human cancers. Many 
cancers overexpress CcnE1 protein or mRNA, including carcinomas (breast, lung, 
cervix, endometrium, gastrointestinal tract), lymphoma, leukemia, sarcomas and 
adrenocortical tumors. CcnE1 overexpression has been shown to predict poor 
survival of patients with breast cancer, non-small-cell lung carcinoma (NSLC), 
squamous cell carcinoma of the larynx and adrenocortical tumors (Hwang and 
Clurman, 2005). Several mechanisms have been shown to deregulate CcnE1 
expression in tumors, such as mutations in regulatory elements of the Rb pathway 
and CcnE1 gene amplifications and disrupted proteolysis. Furthermore, 
overexpression of CcnE low molecular weight (LMW) isoforms increases with the 
loss of p53 control and promotes tumor development (Delk et al., 2009; Wingate et 
al., 2009).  
These data suggest that CcnE1 might be a potential oncogene and its 
overexpression, especially in a hyperstable form, is associated with increased 
incidence of mouse neoplasia and increased susceptibility to the effects of other 
oncogenes (Bortner and Rosenberg, 1997; Loeb et al., 2005; Ma et al., 2007). 
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1.8. Experimental mouse models of HCC 
Several animal models of hepatocarcinogenesis have been described; one 
well established model comprises the single application of diethylnitrosamine (DEN) 
into mice or rats (Heindryckx et al., 2009). DEN has been demonstrated to be a DNA-
reactive carcinogen requiring tissue specific biotransformation for metabolic 
activation. Ethyl-DNA adducts are formed after in vivo exposure to DEN and their 
persistence is related to tumor induction.  
The putative mechanism of DEN induced DNA adduct formation was 
examined by several groups. The first bioactivation step is P450-mediated  
α-hydroxylation, which produces α-hydroxylnitrosamine. DEN is hydroxylated 
principally by the ethanol-inducible CYP2E1 in liver, as well as by other P450 
isozymes (Michejda and Koepke, 1982; Singer and Andrews, 1983; Swenberg et al., 
1991). After DEN is bioactivated to an electrophilic ethyldiazonium ion, it attacks 
nucleophiles, including DNA bases, and forms DNA adducts (Figure 1.3). 
Vulnerability to adduct formation is dependent on individual negative charge at each 
atom on the DNA base, and it is impeded by double stranded hydrogen bonding. A 
single dose of DEN administered i.p. to 10 day old rats induced formation of 58% 
ethyl adducts at the hydrogen linked phosphotriester oxygen, where they should not 
directly cause base mispairing, but might cause strand breaks (Singer, 1985; Singer 
and Andrews, 1983). Consequently, the O6-ethyldeoxyguanosine (O6-EtdG) and the 
O4-ethyldeoxythymidine (O4-EtdT) adducts are most likely the effective mutagenic 
compounds as they are potentially miscoding and are formed in the greatest amounts 
(Boucheron et al., 1987; Saffhill, 1985; Saffhill and Hall, 1985; Singer, 1985). 
All tested species have been found to be susceptible to the carcinogenic 
effects of DEN. In 1967 Hartwell and Shubik (Hartwell, 1967) complied a 
comprehensive review of DEN carcinogenicity testing that was performed between 
1961 and 1967. These authors reported that mice had liver, gastrointestinal, skin, 
respiratory and hematopoietic tumors. In mouse liver, there was evidence of DEN-
related hepatocellular and Kupffer cell tumors. In a study examining DEN and other 
carcinogens in a monkey model, DEN was judged by the authors to be the most 
predictable and potent hepatocarcinogen as compared to 2-acetyl-aminofluorene and 
aflatoxin B1 (Thorgeirsson et al., 1994). Phenotypic changes identified in the 
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neoplastic foci were cytoplasmic basophilia, decreased glucose-6-phosphatase and 
increased glycogen storage (Scherer et al., 1972). Single liver cells that are positive 
for the placental form of gluthatione S-transferase have been found following DEN 
administration and other carcinogens (Moore et al., 1987).  
 
 
 
Figure 1.3 Biotransformation of DEN and DNA adduct formation. DEN is bioactivated in presence 
of oxygen and NADPH and mediated by P450 enzymes into α-hydroxylnitrosamine. Reactive 
ethyldiazonium ion is formed after cleavage of acetaldehyde and reacts with DNA resulting in DNA 
adducts (Verna et al., 1996). 
 
Importantly, it was further shown that three week old rats were more 
susceptible to liver tumors than 20-week-old rats, which was attributed to greater cell 
proliferation in the weanlings (Gray et al., 1991; Peto et al., 1984). 
As stated above, there are many animal studies describing the potent 
carcinogenic effects of DEN exposure and there is also evidence which suggests a 
possible linkage to human cancers as direct dietary sources of DEN have been 
clearly established (Grasso, 1973). The authors report finding levels of DEN 
associated with many human consumables, for example, salted, pickled or smoked 
fish have been found with up to 147 ppb DEN, cooked bacon 17 ppb, whiskey 1,6 
ppb (Sen et al., 1980), and cigarette smoke yielded a range from 0,1 to 8,3 ng 
DEN/cigarette (Hoffmann et al., 1980). 
The purpose of mouse DEN carcinogenicity bioassay is to identify potential 
human liver cancer markers. Single injection of DEN to neonatal mice results in 
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moderate liver damage and formation of DNA adducts which lead to liver tumors 
owing to active hepatocyte proliferation in weanlings. This approach does not reflect 
the features of chronic liver injury that is the leading cause of HCC in humans, 
progressing from fibrosis to cirrhosis and finally to cancer. Therefore it has been 
discussed if DEN is an appropriate model to study human HCC development. 
However, genetic analysis revealed that DEN-induced tumors reflect a gene 
expression profile similar to highly malignant human HCCs with poor prognosis (Lee 
et al., 2004). In addition, besides mouse advantages in breeding capacity and gene 
targeting, DEN allows tumor induction and investigation in an acceptable time.  
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1.9. Aim of the present study 
 
In the past years a variety of studies have indicated an involvement of E-type 
cyclins in cancerogenesis. However, due to the anticipated redundancy of CcnE1 
and CcnE2 the role of each individual E-type cyclin in cancer is poorly investigated. 
The focus of the present study was to analyse in detail the role of CcnE1 and CcnE2 
in hepatocarcinogenesis as many cancers, including hepatocellular carcinoma 
(HCC), overexpress CcnE1, which is associated with reduced patient survival. To 
address this question, the diethylnitrosamine (DEN) model of chemically induced 
HCC will be employed in genetically modified CcnE1-/- and CcnE2-/- mice with the 
ultimate aim to further elucidate the function of both E-type cyclins in liver cancer. 
Specific aims are: 
1. To study how the loss of CcnE1 or CcnE2 affect tumour initiation and 
progression in a model of DEN-induced hepatocarcinogenesis. In this model, 
wildtype mice develop HCC approximately 30-40 weeks after single application of 
DEN. Using both CcnE-/- mice it will be investigated if tumor formation is enhanced, 
or inhibited by the constitutive deletion of a single E-type cyclin. 
2. To characterise tumors derived from constitutive CcnE1 and CcnE2 knockout 
and wildtype mice. The consequence of CcnE ablation with respect to histological 
changes and proliferative response of developed tumors following DEN-treatment will 
be addressed in detail. 
3. To decipher the early and immediate events in liver tumor initiation. To 
address this question, the immediate response after acute DEN liver injury will be 
investigated in order to dissect the impact of CcnE1 or CcnE2 for early oncogenic 
signalling pathways. This model will provide an insight into immediate early events of 
cell transformation. 
4. To prove if the predicted function of E-type cyclins for malignant hepatocyte 
proliferation depends on a functional Cdk2 kinase. The canonical function of CcnE 
involves complex formation with Cdk2 and phosphorylation of downstream targets. 
However, recent data hints at additional non-canonical, Cdk2-independent functions 
for CcnE. Using mice deficient for Cdk2 alone or Cdk2 and CcnE2 the present study 
will address the question if CcnE1 may contribute to hepatocarcinogenesis in a 
Cdk2-independent manner. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals 
 
Reagent Manufacturer 
β-Mercaptoethanol AppliChem, Darmstadt 
Ac-DEVD-AFC Fluorogenic Substrate Biomol, Hamburg 
Acetic acid (glacial) 100% (CH3COOH) Merck, Darmstadt 
Acetone (C3H6O) VWR, Darmstadt 
Acrylamide 30% Bio-Rad, Munich 
Agar-Agar Becton Dickinson, Heidelberg 
Agarose Electrophoresis Grade Serva, Heidelberg 
Albumin bovine Sigma, Steinheim 
Ammoniumperoxodisulfat (H8N2O8S2) Roth, Karlsruhe 
Ampicilin Sigma, Steinheim 
Aprotinin Sigma, Steinheim 
ATP  (Adenosine triphosphate) Invitrogen, Karsruhe 
Boric acid (H3BO3) AppliChem, Darmstadt 
Bromphenol blue Bio-Rad, Munich 
CHAPS (C32H58N2O7S) Sigma, Steinheim 
Chloroform (CHCl3) AppliChem, Darmstadt 
Collagen from rat tail Sigma, Steinheim 
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Reagent Manufacturer 
Complete Mini (protease inhibitors) Roche, Mannheim 
Coomassie Brilliant Blue Bio-Rad, Munich 
DAKO REAL Peroxidase Blocking Solution Dako, Hamburg 
3,3 Diaminobenzidine tablets (Sigma fast) Sigma, Steinheim 
DMF (N,N-Dimethylformamid) ((CH3)2NC(O)H) Sigma, Steinheim 
DMSO (Dimethyl sulfoxide) Sigma, Steinheim 
DNA standard Invitrogen, Karsruhe 
DTT (Dithiothreitol) (C4H10O2S2) Sigma, Steinheim 
EDTA (Ethylene Diamine Tetraacetate)  AppliChem, Darmstadt 
EGTA (Ethylene glycol tetraacetic acid)  AppliChem, Darmstadt 
Eosin Sigma, Steinheim 
Ethanol (C2H5OH) AppliChem, Darmstadt 
Ethidium bromide (C21H20BrN3) Invitrogen, Karsruhe 
Fast Red Tablets Roche, Mannheim 
Fetal bovine serum Invitrogen, Karsruhe 
Formaldehyde 37% (CH2O) Roth, Karlsruhe 
Gelatin from porcine skin Type A Sigma, Steinheim 
Glutaraldehyde (C5H8O2) Roth, Karlsruhe 
Glutathione-Agarose Sigma, Steinheim 
Glycerin (C3H5(OH)3) Roth, Karlsruhe 
Glycerol gelatin Sigma, Steinheim 
Glycine (C8H9NO3) AppliChem, Darmstadt 
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Reagent Manufacturer 
Goat serum Promocell, Heidelberg 
Haematoxylin Sigma, Steinheim 
HEPES (C8H18N2O4S) Roth, Karlsruhe 
Hydrogen peroxide 30% (H2O2) AppliChem, Darmstadt 
Hydrochloric acid (HCl) Merck, Darmstadt 
Isopropyl alcohol (C3H8O) AppliChem, Darmstadt 
IPTG Sigma, Steinheim 
L-Glutathione reduced Sigma, Steinheim 
Lymphocyte LSM 1077 PAA, Cölbe 
Magnesium chloride (MgCl2) Merck, Darmstadt 
Methanol (CH4O) VWR, Darmstadt 
Nonfat dried milk powder AppliChem, Darmstadt 
Nonidet P-40 AppliChem, Darmstadt 
Novex Sharp protein standard Invitrogen, Karsruhe 
Nuclear Fast Red Solution Sigma, Steinheim 
Phenilenediamine dihydrochloride  Sigma, Steinheim 
32P gamma-ATP Hartmann, Braunschweig 
Paraformaldehyd ((CH2O)n) Roth, Karlsruhe 
Pefabloc SC Protease Inhibitor Roth, Karlsruhe 
Penicillin-Streptomycin Invitrogen, Karsruhe 
peqGOLD RNA PureTM Peqlab, Erlangen 
PhosSTOP Roche, Mannheim 
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Reagent Manufacturer 
PIPES (C8H18N2O6S2) Sigma, Steinheim 
PMSF (Phenylmethylsulphonyl fluoride)  Roth, Karlsruhe 
Poly dI:dC GE Healthcare, Munich 
Ponceau S Sigma, Steinheim 
Potassium chloride (KCl) Merck, Darmstadt 
Potassium Ferricyanide (C6N6FeK3) Sigma, Steinheim 
Potassium Ferrocyanide (C6N6FeK4) Sigma, Steinheim 
Roti-Histokit Roth, Karlsruhe 
SDS (Sodium Dodecylsulfate) (NaC12H25SO4) Roth, Karlsruhe 
Serum, human Sigma, Steinheim 
Serum, mouse Sigma, Steinheim 
Serum, rabbit Sigma, Steinheim 
SIGMA FAST 3,3´-Diaminobenzidine tablets Sigma, Steinheim 
Silver nitrate (AgNO3) Merck, Darmstadt 
Sodium acetate anhydrous (C2H3NaO2) AppliChem, Darmstadt 
Sodium azide (NaN3) AppliChem, Darmstadt 
Sodium tetraborate anhydrous (Na2B4O7) Sigma, Steinheim 
Sodium carbonate (Na2CO3) Merck, Darmstadt 
Sodium chloride (NaCl) AppliChem, Darmstadt 
Sodium fluoride (NaF) Sigma, Steinheim 
Sodium hydroxide (NaOH) 1 mol/l AppliChem, Darmstadt 
Sodium hydroxide pellets Merck, Darmstadt 
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Reagent Manufacturer 
Sodium orthovanadate (Na3VO4) AppliChem, Darmstadt 
Sodium thiosulfate (Na2S2O3) Sigma, Steinheim 
SuperSignal West Pico Substrate Thermo Scientific, Bonn 
TEMED (Tetramethylethylenediamine)  Bio-Rad, Munich 
Tissue Tek Dako, Hamburg 
Trichloroacetic acid (C2HCl3O2) Merck, Darmstadt 
Trypsin Inhibitor Sigma, Steinheim 
Tris (C4H11NO3) AppliChem, Darmstadt 
Tri-sodium citrate dihydrate (Na3C6H5O7·2HCl) Roth, Karlsruhe 
Triton X100 Roth, Karlsruhe 
Trypton Becton Dickinson, Heidelberg 
Tween® 20 Sigma, Steinheim 
Vectashield mounting medium with DAPI Dako, Hamburg 
Vectastain ABC Kit  Dako, Hamburg 
X-gal (5-bromo-4-chloro-3-indolyl β-D-galacto-
pyranoside) 
Sigma, Steinheim 
Xylene VWR, Darmstadt 
Xylene cyanole FF (C25H27N2NaO6S2) Sigma, Steinheim 
Yeast extract Becton Dickinson, Heidelberg 
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2.1.2. Standard buffer and media 
Buffers Manufacturer 
Phosphate buffered saline (PBS) PAA, Cölbe 
Restore Western Blot Stripping Buffer Thermo Scientific, Bonn 
Roti Block 10x Roth, Karlsruhe 
Rothiphorese10x SDS PAGE Roth, Karlsruhe 
TAE 50x AppliChem, Darmstadt 
 
Cell culture medium Manufacturer 
DMEM (Dulbeco’s Modified Eagle Medium) PAA, Cölbe 
EBSS (Earle's Balanced Salt Solution) w/o Ca2+ & Mg2+ Invitrogen, Karsruhe 
EBSS (Earle's Balanced Salt Solution) with Ca2+ & Mg2+ Invitrogen, Karsruhe 
HBSS (Hank’s Balanced Salt Solution) PAA, Cölbe 
RPMI (Roswell Park Memorial Institute) PAA, Cölbe 
 
2.1.3. Standard kits and enzymes 
Kit / Assay Manufacturer 
BIO-RAD Protein Assay Bio-Rad, Munich 
In Situ Cell Death Detection Kit, Fluorescein Roche, Mannheim 
Omniscript RT Kit Qiagen, Hilden 
OxiSelect Oxidative DNA Damage 
Quatitation Kit (AP sites) 
Cell Biolabs / Biocat, Heidelberg 
Pierce Crosslink Immunoprecipitation Kit Thermo Scientific, Bonn 
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Enzyme Manufacturer 
Collagenase Type II CellSystems, Troisdorf 
HotStarTaqTM Master Mix Qiagen, Hilden 
Liberase Roche, Mannheim 
Proteinase K – Solution AppliChem, Darmstadt 
ReadyMixTM redtaqTM PCR reaction mix 
with MgCl2 
Sigma, Steinheim 
RNAse Sigma, Steinheim 
SYBR® GreenERTM qPCR Super Mix Invitrogen, Karlsruhe 
 
2.1.4. Diverse 
Diverse products Manufacturer 
Hyperfilm GE Healthcare, München 
Novex® Midi Gel System Invitrogen, Karsruhe 
Oligo DT  Qiagen, Hilden 
Protein A/G PLUS – Agarose 
Immunoprecipitation Reagent 
Santa Cruz, Heidelberg 
PROTRAN® Nitrocellulose Transfer Membrane Whatman GmbH, Dassel 
PureLinkTM HiPure Precipitator Module Invitrogen, Karsruhe 
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2.1.5. Antibodies used for immunostaining and/or western blot 
Primary Antibody Catalog Number Company 
CD11b 550282 BD 
Cleaved caspase-3 #9661 Cell Signaling 
F4/80 MCA497GA AbD serotec 
Ki67 discontinued Dianova 
Ly6G 550291 BD 
p21 sc-397 Santa Cruz 
p27 #3698 Cell Signaling 
p27 554069 BD 
p-p27 sc-16324 Santa Cruz 
PCNA 13-3900 Invitrogen 
pH2A.X #2577 Cell Signaling 
p53 #9284 Cell Signaling 
pJNK1/2 #9251 Cell Signaling 
 
Secondary Antibody Catalog Number Company 
Anti-rabbit HRP #7074 Cell Signaling 
Anti-mouse HRP sc-2954 Santa Cruz 
Anti-goat HRP sc-2768 Santa Cruz 
Anti-rat HRP sc-2956 Santa Cruz 
Alexa Fluor488 anti-mouse A-11059 Invitrogen 
Alexa Fluor 488 anti-rabbit A-11008 Invitrogen 
Alexa Fluor 546 anti-rabbit A-11071 Invitrogen 
Alexa Fluor 594 anti-rabbit A-11072 Invitrogen 
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2.1.6. Primer sequences used for Q-RT-PCR 
Gene Forward Reverse 
Bax CGAGCTGATCAGAACCATCA GGTCCCGAAGTAGGAGAGGA 
Bcl2 GCTGAGCAGGGTCTTCAGAG AGTACCTGAACCGGCATCTG 
Bcl-6 AGTTTCTAGGAAAGGCCGGA GATACAGCTGTCAGCCGGG 
Bcl-XL GCTGCATTGTTCCCGTAGAG GTTGGATGGCCACCTATCTG 
Bim GCCCCTACCTCCCTACAGAC GCTCCTGTGCAATCCGTATC 
bNIP3 TGTCGCAGTTGGGTTCG CCATTGCCATTGCTGAAGTG 
Cat AAAACGATAATCCGGGCTTC TTGCTAAGCCCTAACCTTTCA 
Ccna2 GTGGTGATTCAAAACTGCCA AGAGTGTGAAGATGCCCTGG 
Ccne1 TCCACGCATGCTGAATTATC TTGCAAGACCCAGATGAAGA 
Ccne2 AAAAAGTCTTGGGCAAGGTAAA GCATTCTGACCTGGAACCAC 
Ccnd1 AAGCATGCACAGACCTTTGTGG TTCAGGCCTTGCATCGCAGC 
E2F1 AGAGTGAGCAGCAGCTGGAT GGTCCTGGCAGGTCACATAG 
E2F2 AGTTGCTCCCTGAGCTTCAA GCTCCTTGAAGTTGCCTACG 
Fas (CD95) TCCAGAAGGACCTTGGAAAA CCTCTCTTCATGGCTGGAAC 
FasL GTTTTCTGAGCCGACCTTTG TCATTGCACTGGAGGTATGC 
Fibronectin ACCTCTGCAGACCTACCCAG TTGGTGATGTGTGAAGGCTC 
GADD45α ACCCTCATCCGTGCGTTCT TCCAGTAGCAGCAGCTCAGCTA 
GAPDH TGTTGAAGTCACAGGAGACAACCT AACCTGCCAAGTATGATGACATCA 
IL-6 CTTCCATCCAGTTGCCTTCTT AATTAAGCCTCCGACTTGTGAAG 
Mdm2 AGAAGGAGATCCATTAGTGAGACA TCCCTCAGCTCACACAGACC 
MnSOD AGCATTTAGGGTTCCCTTGC GACCCAATGAGCCAAAGAAA 
Noxa CTGAGATGCCCGGGAGAA CCACGTGCAATACACTTTGTC 
p16 CTTTGTGTACCGCTGGGAAC CTGAGGCCGGATTTAGCTCT 
p19 GCTCTGGCTTTCGTGAACAT TGAGCAGAAGAGCTGCTACG 
p21 TTGCACTCTGGTGTCTGAGC TCTGCGCTTGGAGTGATAGA 
p27 GACAATCAGGCTGGGTTAGC TCTGTTCTGTTGGCCCTTTT 
p53 AAAGGATGCCCATGCTACAG TATGGCGGGAAGTAGACTGG 
Puma ACCTCAACGCGCAGTACG GGGAGGAGTCCCATGAAGAG 
Smarca4 CCCACGTTTCTTCTGCTTCT ACGTAAGCGTAAGCGAGACA 
Smarcc1 TCCTGAGTACGGCTTCCAAC TGGAAGGGAGTGGACAGAAC 
TRAIL TGGAGTCCCAGAAATCCTCA TCACCAACGAGATGAAGCAG 
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2.1.7. Primer sequences used for genotyping PCR  
Mouse strain Primer name sequence 
CcnE1-/- 
E11-A CGCCATGGTTATCCGGGAGATGG 
11-2 CGCATACTGAGACACAGACT 
3N3 GATCTCTCGTGGGATCATTG 
CcnE2-/- 
E2G GGTTCTCCCATTTAGAGCACAG 
E2L GCTATAGCAGTTGTTTCTGTTTG 
3N3 GATCTCTCGTGGGATCATTG 
Cdk2Δhepa 
Cdk2-3B8 CAAGTTGACGGGAGAAGTTGTG 
Cdk2-3B9 GAAGACCCTCCAGGTGAATGAA 
Cdk2Δhepa 
Cdk2 exon1 GGAGAACTTCCAAAAGGTGGA 
Cdk2 exon4 ACAGGGACTCCAAAGGCTCT 
 
 
2.1.8. Instruments and other equipment 
Instruments Manufacturer 
AxioImager Z1 Carl Zeiss, Jena 
Blotting chamber Trans-Blot cell Biorad, Munich 
Bright Field Microscope DM1000 Leica, Wetzlar 
Cell culture bench BSB6A 
Gelaire Flow Laboratories, 
Meckenheim 
Cell incubator Haereus BB 6220 Thermo Scientific, Dreieich 
Centrifuge Eppendorf Tabletop 5417 Eppendorf, Hamburg 
Centrifuge Heraeus-Kendro 
Megafuge 1.0R 
Thermo Scientific, Dreieich 
Centrifuge Heraeus Pico 17 Thermo Scientific, Dreieich 
Cryostat HM 550 Microm Thermo Scientific, Dreieich 
DISKUS Z16 APO Leica, Wetzlar 
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FACS Canto II Flow Cytometer BD, Erlangen 
FUJI FILM LAS-4000 FUJI FILM Europe, Düsseldorf 
Gel chamber Subcell GT Biorad, München 
Gel chamber  Peqlab, Erlangen  
Homogenizer Janke & Kunkel, Staufen 
Microcentrifuge IR 220 VAC Roth, Karlsruhe 
Real-Time PCR System 7300 Applied Biosystems, Darmstadt 
Thermocycler T3000 Biometra, Göttingen 
Thermomixer Eppendorf, Hamburg 
Vortex Reax top Heidolph, Nürnberg 
  
Plastic and Glassware Manufacturer 
Beakers (10 – 1000 mL) Schott-Duran, Mainz 
Bottles (25- 2000 mL) Schott-Duran, Mainz 
SuperFrost slides Roth, Karlsruhe 
Pasteur pipettes Brand, Giessen 
96-well plates for RNA/DNA measurement Greiner Bio-one, Frickenhausen 
96-well plates for protein measurement Greiner Bio-one, Frickenhausen 
96-well plates for Real-Time PCR StarLab, Ahrensburg 
Pipettes tips with filter for liquid handling 
VWR, Darmstadt; BioHit, 
Rosbach v.d. Höhe; Biozym, 
Hess. Oldendorf 
Reaction tubes (0,5 – 2mL) Eppendorf, Hamburg 
8 vial strips for PCR (0,2mL) Sarstedt, Nümbrecht 
Reaction tubes 15mL Sarstedt, Nümbrecht 
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Reaction tubes 50 mL GreinerBio-one, Frickenhausen 
Sterile pipettes (2-50mL) Sarstedt, Nümbrecht 
Cell Strainer (70 µm) BD, Erlangen 
Cryotubes 1,5 mL Nunc, Langenselbold 
6; 12; 24-well plates BD-Falcon, Heidelberg 
 
Animal experiment consumables Manufacturer 
General chow for rodents Altromin, Lage 
Hematocrit capillary Hirschmann Laborgeräte, Eberstadt 
Heparine (Liquemin(R))  Roche, Mannheim 
Injection needles Sterican(R)  Braun, Melsungen 
Isoflurane Abbott, Ludwigshafen 
Ketamin 10% CEVA TIERGESUNDHEIT GmbH, 
Düsseldorf 
Micro tube (1,1 ml Z-Gel) Sarstedt, Nümbrecht 
Sodium chloride 0,9% (NaCl) DeltaSelect, Dreieich 
Sunflower seed oil Sigma, Steinheim 
Surgical instruments FST, Heidelberg 
Syringe Omnican(R)  Braun, Melsungen 
Xylazin 2%  Bernburg Medistar, Holzwickede 
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2.2. Methods 
2.2.1. Animal maintenance and treatments 
All mice were bred and maintained under specific pathogen-free conditions at 
the animal facility of the University Hospital Aachen. Upon approval by the local 
government (AZ 8.87-50.10.35.08.284), all experiments were performed in 
accordance with the German legislation on protection of animals and the National 
Institutes of Health ´Guide for the Care and Use of Laboratory Animals` (Institute of 
Laboratory Animal Resources, National Research Council; NIH publication 86-23 
revised 1985). Mice were housed in macrolon cages providing food and water ad 
libitum and were grouped up to 5-10 animals per cage. Tail biopsies for genotyping 
were taken after weaning and ear marking. 
 
 
 
 
Figure 2.1 Experimental designs. (A) Induction of cancer with a single injection of diethylnitrosamine 
(DEN) at the day 14 and follow up at the age of 24 or 40 weeks. (B) Induction of acute liver injury with 
high dose of DEN and liver and/or blood sampling at 0, 24, 48, 72, 96, 168 and 240 hours after 
injection. 
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Wild type, CcnE1 and CcnE2 knockout mice were kept on a 129/ola 
background. Hepatocyte specific Cdk2 knockout was generated by crossing Cdk2f/f 
mice (Ortega et al., 2003) with Alb-cre mice (Kellendonk et al., 2000). CcnE2 
knockout mice were crossed with Cdk2f/f Alb-cre mice to generate double deficient 
animals. These animals were intercrossed at least six times.  
For hepatocarcinogenesis, a single dose of DEN (25 mg/kg body weight) was 
injected intraperitoneally at two weeks of age. After 4 or 8 months on normal chow, 
male mice were sacrificed, their livers were removed and analysed for the presence 
of HCCs.  To induce acute liver damage, 6-8 week old male animals were injected 
intraperitoneally with 200mg/kg DEN, livers were removed 24 to 240 hours after 
injection and analysed (Figure 2.1).  
 
2.2.2. Genotyping 
The correct genotypes were verified by PCR analysis. DNA was prepared from 
fresh mouse tail biopsies using NID buffer.  Mouse tails were digested with 200µl of 
NID buffer and 1µl of proteinase K at 56°C overnight. Enzyme activity was stopped 
by heating at 95°C for 5 minutes. The hairs were shortly spun down and 2µl of the 
supernatant was used for PCR reaction. 
  
NID buffer content End concentration 
KCl 0.05 M 
Tris 0.01 M 
MgCl2 2 mM 
Gelatine type 3 0.1 mg/ml 
NP-40 0.45 % 
Tween 20 0.45 % 
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PCR reaction and programs were as follows: 
Reaction volume 25 µl 
Primer sense (0,1nmol) 1 µl 
Primer antisense (0,1nmol) 1 µl 
Polymerase mix * 12.5 µl * ReadyMix
TM
 redtaq
TM
  or HotStarTaq
TM
 Master Mix  
dH2O 8.5 µl 
DNA template 2 µl 
 
 
 
Stage Cyclins PCR Cre PCR CDK2
f/f
 PCR cycles 
 temp time temp time temp time  
Denaturation 95°C 2 min 98°C 2 min 95°C 15 min 1 
Denaturation 98°C 15 sec 95°C 15 sec 98°C 20 sec 
33-36 Annealing 52°C 30 sec 54°C 30 sec 56°C 30 sec 
Elongation 72°C 30 sec 72°C 30 sec 72°C 1 min 
Additional 
elongation 
72°C 2 min 72°C 5 min 72°C 5 min 1 
 
PCR products were separated by size on 2% (w/v) agarose gels. The agarose 
was boiled in TAE buffer, cooled at RT for 5-10 min, and 0.4 µg/ml ethidium bromide 
(EtBr) was added. 5x loading dye were added to the samples before application to 
the gel slots. Gels were run in TAE at 60-120 V. DNA markers were used to 
determine the specific size of fragments. EtBr, which intercalates into the DNA, 
enabled the visualisation of the DNA on a UV-transilluminator.  
 
2.2.3. Blood sampling and serology 
Blood sampling was performed in mice under transient anaesthesia with 
Isoflurane by penetrating the retro-orbital sinus with a glass capillary. Blood samples 
were collected in a serum tube and centrifuged at 5000g for 10 minutes. Serum was 
transferred into a fresh tube and stored at -20°C. Serum transaminases are specific 
markers for liver damage. In this study, measurement of ALT and AST (alanine-
aminotransferase and aspartate-aminotransferase, respectively) was performed in 
Materials and Methods 
31 
 
the clinical routine laboratories of the Institute of Clinical Chemistry and 
Pathobiochemistry, UK Aachen. 
 
2.2.4. Extraction and sectioning of livers 
Mice were sacrificed by cervical dislocation; the abdominal cavity was cut 
open along the Linea alba. Two relaxation cuts were placed along the costal arches 
at the lateral abdominal walls and liver was removed by dissecting the ligaments and 
placed in ice cold PBS.  
 
Papillary 
process
Caudate lobe
Left lateral 
lobe
Right lateral 
lobe
Right medial lobe
Left medial lobe
Gall bladder
 
Figure 2.2 Mouse liver. Visceral aspect indicating cut levels for sampling (Ruehl-Fehlert et al., 2003). 
 
The gall bladder was removed, third of left lateral lobe, right lateral and 
caudate lobe were embedded in Tissue-Tek and stored at -80°C. Middle third of left 
lateral lobe and half of right medial lobe were placed in 4% PFA for paraffin 
embedding. Third of left lateral lobe, left medial lobe, half of right medial lobe and 
papillary process were snap frozen in liquid nitrogen and stored at -80°C.  
 
2.2.5. Assessment of HCC 
Immediately after sacrifice, visible tumors were counted and the size was 
measured using calliper and Diskus system (Leica).  
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2.2.6. Liver perfusion and isolation of primary hepatocytes 
The mice were anaesthetized by intraperitoneal injection of ~300 μl of 
Ketamin-Xylazin solution. Anesthetized mice were immobilized with tape on all four 
limbs, the abdomen was opened and intestine was moved aside to expose the vena 
portae. The cannula was inserted in the portal vein and was fixed with a nylon 
monofilament wire to avoid that the blood pressure removes the needle at the 
beginning of the perfusion. Perfusion was started with 30 ml solution A, pH 7.4. As 
soon as the perfusion is started, the hepatic vein was immediately cut to allow 
perfusate to run out. Liver was perfused with a flow rate of 5 ml/min. Next, the liver 
was perfused with 30 ml of B solution pH 7.4.  Finally, perfusing was switched to 
solution C with collagenase. At this stage the hepatic tissue was rapidly 
disaggregated. The tissue was collected and transferred into a plate, gallbladder was 
removed, and the liver tissue is swirled around to wash hepatocytes out.  
Perfusion 
solutions 
Content Amount 
Solution A 
 
EBSS without Ca2+ & Mg2+ 
EGTA 
50 ml 
100 mM 
Solution B 
 
EBSS with Ca2+ & Mg2+ 
HEPES, pH 7.4 
30 ml 
10 mM 
Solution C 
 
 
 
EBSS with Ca2+ & Mg2+ 
HEPES, pH 7.4 
Collagenase 
Soybean trypsin inhibitor 
50 ml 
10 mM 
0.3 mg/ml 
0.04 mg/ml 
 
Anesthesia Volume (µl) 
Ketamin 450 
Xylazin 50 
NaCl  0.9% 4500 
 
Hepatocytes and remaining tissue were collected in 5 ml DMEM and filtered 
cells through a 70 μm cell strainer. Cells were centrifuged at 500rpm for 1min at room 
temperature. Pellet was washed with PBS two times. Supernatant was removed and 
the pellet was resuspended in 20 ml high glucose DMEM supplemented with serum 
(10% FCS) and antibiotics (Penicillin, Streptomycin). The hepatocytes were counted 
and plated on precoated plates (Collagen from mouse tail). Mouse primary 
hepatocytes were cultured in DMEM/high glucose media supplemented with 10% 
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FCS in a humidified atmosphere containing 5% CO2 at 37°C. The cells were grown in 
100 mm dishes, 6-well or 96-well plates. The cells were allowed to settle down and 
adhere to culture dishes for 4-5h and then the medium was replaced with fresh one 
or immediately stimulated. 
 
2.2.7. Mouse primary hepatocyte culture 
Mouse primary hepatocytes were cultured in DMEM/high glucose media 
supplemented with 10% FCS in a humidified atmosphere containing 5% CO2 at 37°C. 
106 hepatocytes were grown in 100 mm dishes and stimulated with 5 mM DEN for 24 
hours following 24, 48 or 72 hours stimulation with EGF (10 ng/ml) and Insulin (20 
U/µl), cells were harvested and stored at -80°C. In a 6-well 1.5 x 105 hepatocytes 
were grown and stimulated as well with 5 mM DEN and EGF/Insulin.  
 
Figure 2.3 Cell culture experimental design. Primary hepatocytes were treated with 5 mM DEN for 
24 hours and/or subsequently with EGF and Insulin for further 24, 48 or 72 hours. 
 
2.2.8. Flow cytometry 
Hepatic immune cells and cultured primary hepatocytes were passed through 
a fluorescence-activated cell sorter (FACS) in order to characterize immune cell 
populations in the liver and DNA content in cultured primary hepatocytes. 
Fluorescent markers that specifically stain relevant cellular molecules are detected by 
FACS and thus allow determination of the number of stained cells as well as the 
intensity of staining in each cell.  
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DNA content in primary hepatocytes after DEN and EGF/Insulin stimulation 
was determined with propidium iodide staining. Propidium iodide stains the DNA and 
RNA in cells, the intensity of the fluorescence of each cell can be correlated with the 
cell’s DNA content, which in turn correlates with the cell cycle phase. Cells were 
detached from Petri dishes using 750 µl acutase per 6-well for 15 minutes at 37°C 
and collected. After washing with PBS, cells were fixed in 4% PFA for 15 minutes at 
RT. Permeabilization was performed with 0.1% Na-Citrate, 0.1% Triton-100x in H2O, 
for 20 minutes at RT. Cells were washed with PBS and stained, 500µl of PI staining 
solution per stain was used and measured within 30 minutes. 
 
2.2.9. RNA extraction, cDNA preparation, Real-Time PCR 
RNA was extracted from mouse livers or primary hepatocytes using peqGOLD 
RNA PureTM (Peqlab) following manufacturer’s instructions. A piece of liver tissue 
was minced in peqGOLD RNA with an electric homogenizer. Lysates were incubated 
at room temperature for five minutes. After addition of 0.2 volumes of chloroform to 
the supernatants followed by centrifugation at 12000g, the upper phases were 
incubated 10 minutes with isopropanol and RNA was pelleted by centrifugation at 
12000g at 4°C. The pellets were washed two times with1 ml of 70% ethanol, air dried 
for 5 minutes and eluted in RNAse-free water. RNAs were quantified by 
spectrophotometry at an optical density (OD) of 260 nm. A 260/280 ratio ≥1.8 was 
considered high purity. 
Reverse transcription reaction mix Volume per reaction 
10x Buffer RT 2 µl 
dNTP mix  2 µl 
Oligo DT 2 µl 
Omniscript Reverse transcriptase 1 µl 
Template RNA (1µg/µl) 2 µl 
Total reaction volume 20 µl 
 
Reverse transcription was performed using an Omniscript kit (Qiagen) 
according to the manufacturer’s protocol. Reactions were carried out in 20 μl 
volumes. Reactions were incubated in a PCR thermocycler at 37°C for 60 min, and 
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95°C for 5 min and then cooled to 4°C. After reverse transcriptase, samples were 
diluted by adding purified water.  
For real-time quantitative RT-PCR, the Real-Time PCR System (AB 7300) was 
used. RT-PCR was performed in duplicate in 25 μl reaction volumes. Three-step 
PCR cycling was carried out as follows: 50 °C for 2 min (1 cycle), 95°C for 10 min 
(1 cycle), 95°C for 15 s, and 60°C for 1 min (40 cycles). At the end of the PCR, 
baselines and threshold values were established using AB 7300 System SDS 
software, and the Ct values were exported to Microsoft Excel (Microsoft Corp., 
Redmond, WA) for analysis. Expression of mRNA was calculated using a relative 
quantification method (Pfaffl, 2001), which determines the relative quantification of a 
target gene in comparison to a reference gene. Analysis was carried out using the 
sequence detection software supplied with the AB 7300. This software calculates the 
Ct for each reaction and uses it to quantify the amount of starting template in the 
reaction. The relative expression ratio of a target gene is calculated based Ct 
deviation of an unknown sample versus a control and is expressed in comparison to 
the reference gene GAPDH. 
Real-time PCR reaction mix Volume per reaction 
Primer sense 2 µl 
Primer antisense 2 µl 
SYBR green 12.5 µl 
cDNA 5 µl 
dH2O 3.5 µl 
Total reaction volume 25 µl 
  
2.2.10. DNA isolation from frozen livers 
A small piece of frozen liver was incubated in 700 µl of lysis buffer (50 mM 
Tris-HCl pH 8, 100 mM EDTA pH 8, 100 mM NaCl, 1% SDS) supplemented with 35 
µl proteinase K and incubated at 37°C, 350 rpm on a thermomixer overnight. The 
solution was centrifuged at 5000g and 4°C for 5 minutes, supernatant containing 
DNA was transferred in a clean microcentifuge tube and precipitated with 800 µl 
isopropanol. After centrifugation at 13000g, 4°C for 10 minutes, the supernatant was 
discarded and pellet was washed twice with 1 ml of cold 70 % ethanol. Pellet was 
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dissolved in 50 µl TE buffer (10 mM Tris, pH 7.5 with 1 mM EDTA) and concentration 
was determined by measuring OD at 260. A 260/280 ratio ≥1.8 was considered high 
purity.  
 
2.2.11. DNA labelling and measuring of AP sites 
AP sites are apurinic/apyrimidinic (abasic) sites in DNA, resembling one of the 
prevalent lesions of oxidative DNA damage. Unrepaired abasic site inhibit 
topoisomerase, replication and transcription, can be mutagenic because of bypass 
synthesis on nontemplated DNA. The measurement of AP sites was done by 
comparing samples to the standard curve using OxiSelect Oxidative DNA Damage 
Quantitation Kit (AP sites). Genomic DNA was labelled with ARP (Aldehyde Reactive 
Probe) using OxiSelect Oxidative DNA Damage Quantitation Kit (AP sites) following 
manufacturer’s instructions.  
 
2.2.12. Whole cell protein extracts 
A piece of frozen liver was minced in NP-40 protein extraction buffer and 
centrifuged 10 min at 12000g, 4 °C. In case of cultured cells, hepatocytes were 
collected in PBS to microcentrifuge tube, spun down 1 min at 500 rpm, supernatant 
was removed. Pellet was resuspended in NP-40 protein extraction buffer, then snap 
frozen and warmed up few times to break the cell membrane and finally centrifuged 
10 min at 12000g, 4 °C.  Supernatant with whole cell proteins was aliquoted and 
frozen at -80 °C. 
NP-40 protein extraction buffer 
Tris-HCl pH 7.5 50 mM 
NaCl 150 mM 
NP-40 0.50% 
NaF 50 mM 
Na3VO4 1 mM 
DTT 1 mM 
PMSF 1 mM 
1 Complete mini tablet per 10 ml buffer 
1 PhosSTOP tablet per 10 ml buffer 
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2.2.13. Isolation of nuclear and cytoplasmic cell fractions  
A piece of frozen liver was minced in buffer A, incubated for 10 min at 4 °C. 
10% of NP-40 added, mixed with tipping the tube, and incubated at 4°C for 1 min.  
Nuclei were pelleted for 1 min at 10000 rpm and 4 °C. Supernatant was saved and 
frozen at -80 °C as cytoplasm fraction. Nuclei pellet was washed with 1 ml of buffer A 
2-3 times. Pellet was resuspended in buffer C, incubated 30 min on ice, mixed gently, 
and spun down 10 min at 10000 rpm, 4 °C. Nuclear proteins (supernatant) were 
saved and frozen at -80 °C. Buffers A and C are made as follows: 
 
 
 
 
2.2.14. Protein concentration measurement 
The concentration of whole protein extracts was performed using BIO-RAD 
Protein Assay reagent. This technique was first described by Bradford et al. 
(Bradford, 1976) and based on the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein 
occurs. According to manufacturer’s protocol protein and standard were measured in 
a spectrophotometer at OD595. The OD595 of each sample was compared to a 
standard curve prepared with BSA. 
Nuclear extract concentrations were measured using Bio-Rad Dc Protein 
Assay because of higher sensitivity for low protein concentrations. According to 
manufacturer’s protocol, protein and standard were measured in a 
spectrophotometer at OD750. The OD750 of each sample was compared to a standard 
curve prepared with BSA. 
Buffer A Buffer C 
HEPES pH 7.6 10 mM HEPES pH 7.8 50 mM 
MgCl2 2 mM KCl 50 mM 
KCl 10 mM NaCl 300 mM 
EDTA 0.1 mM EDTA 0.1 mM 
 + Protease inhibitors 
Glycerol 10% 
 + Protease inhibitors 
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2.2.15. Western Blot 
Protein samples were separated electrophoretically on 10%, 12% or 15% 
denaturing SDS-polyacrylamide gel or on pre-cast 4-12% polyacrylamide gel 
(Invitrogen). Gel and buffer were prepared according to table (Laemmli, 1970):  
 
5x Protein loading buffer 1x SDS Running buffer 
Tris-HCl pH 6.8 125 mM Tris-Base 1.25 M 
Glycerol 50% Glycine 2 M 
SDS 5% SDS 1% 
Bromphenol blue 0.025% 
 
β-Mercaptoethanol 50 µl per 1 ml loading buffer 
 
In short, 5x Protein loading buffer was added to each sample in appropriate 
volumes and samples were boiled at 96 °C for 5 min before loading to the gel slot. 
Separation was performed in 1x SDS running buffer at 50-80 V overnight or in MOPS 
running buffer at 120 V for approximately 2 h (pre-cast gel system). For 
immunological detection, the separated proteins in gel were transferred to a 
nitrocellulose membrane.  
 
Reagent Resolving Gel Stacking Gel 
Percent 10% 12.5% 15% 5% 
dH2O 20 ml 16.4 ml 12.3 ml 13 ml 
1.5M Tris-HCl, pH 8.8 12.5 ml 12.5 ml 12.5 ml - 
0.5M Tris-HCl, pH 6.8 - - - 6,25 ml 
30% Acrilamide 16.5 ml 20.3 ml 24.35 ml 5 ml 
10 % SDS 500 µl 500 µl 500 µl 250 µl 
10 % APS 500 µl 500 µl 500 µl 500 µl 
100 % TEMED 37.5 µl 37.5 µl 37.5 µl 37.5 µl 
 
A wet blotting chamber (Peqlab) was used to transfer the separated proteins 
from the polyacrilamide gel to a nitrocellulose membrane. Whatman paper, 
nitrocellulose membrane and polyacrilamide gel were soaked in transfer buffer. 
Transfer was performed according to standard proceedings.  
Materials and Methods 
39 
 
20x MOPS running buffer (500 ml) 
Reagent Mass (gram) Final concentration (1x) 
MOPS 104.6  50 mM 
Tris base 60.6 50 mM 
SDS 10.0 3.5 mM 
EDTA 3.0 1 mM 
 
Successful transfer and equal loading was confirmed by Ponceau Red 
staining. For immunological detections, the non-specific binding sites were blocked 
for 1.5 hours in 5%  non-fat dry milk diluted in PBS-Tween (PBST) or in 1x Roti-block. 
The membrane was shortly washed and then incubated overnight at 4 °C in PBST 
with primary antibody at optimized dilutions. The membrane was washed 3x5 min in 
PBST and then incubated with secondary antibody diluted 1:5000 in PBST for 1h at 
RT. After incubation, the membrane was washed 3x5 min in PBST and then 
incubated in ECL Substrate (Pierce) for 5 min. The membrane was exposed to 
hyperfilm (Amersham) or a digital detection system (FUJIFILM).  
 
2.2.16. Immunoprecipitation Assay 
Protein-protein interactions were identified by immunoprecipitation 
experiments using protein A/G agarose beads. Total protein extracts (1 mg in 500 µl 
volume) were precleared with protein A/G agarose beads to remove all proteins that 
bind unspecific to the beads and murine immunoglobulin for 2 hours at 4°C on 
overhead shaker. The mixture was centrifuged at 2000g at 4°C, the pellet was 
discarded and the supernatant was transferred into fresh tube and incubated with 4 
µl of antibody at 4°C with overhead rotation overnight. Immunoprecipitated 
complexes were collected with 40 µl of protein A/G agarose beads for 1 hour, then 
spun down and pellet was washed twice with 1 ml of cold NP40 buffer. Protein-
protein-antibody complexes were dissolved from the beads by denaturation in 10 µl 
5x SDS loading buffer supplemented with β-mercaptoethanol and boiling at 95°C for 
10 minutes. Agarose beads were spun down at 12000 rpm and the supernatant 
containing precipitated proteins was loaded on SDS PAGE gel or stored at  -20C° 
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2.2.17. Gel silver staining 
SDS-PAGE was fixed directly after running in a mixture of 40% ethanol and 
10% acetic acid for 30 minutes. The fixed gel was then incubated in sensitizer 
(30% EtOH, 0.2% sodium thiosulphate, 7% sodium acetate) for 30 min and 
washed with dH2O three times 5 min before silver staining. Silver staining was 
performed with 0.5 % silver nitrate for approximately 10 min. After washing for 5 
min with dH2O, gel was developed with 2.5% sodium carbonate and 0.02% 
formaldehyde mixture until bands are clearly seen (approx. 3-4 min). The 
developing reaction was stopped with 0.5% Glycine for 30 min. All reactions were 
performed at RT.  
 
2.2.18. Caspase 3 Assay 
For protein extractions from frozen livers, AFC lysis buffer was used. Samples 
were shock frozen in liquid nitrogen and stored at -80°C. 
 
AFC Lysis buffer End concentration 
Hepes pH 7.4 10 mM 
Chaps 0.1 % 
EDTA pH 8 2 mM 
DTT 5 mM 
Pefa Block 1 mM 
Complete mini 1 tablet 
 
Caspases-3 is a key enzyme in apoptosis. The assay made use of a Caspase-
3 specific substrate (DEVD) linked to a fluorochrome (AFC). Active Caspase-3 
specifically cleaves the substrate DEVD between D and AFC, thus releasing free 
AFC which can be quantified by UV spectrofluorometry. These tetrapeptide 
substrates are used to identify and quantify Caspase-3 activity in apoptotic protein 
lysates. Per reaction tube 487.5 μl master mix and 12.5 μl proteins were mixed. 
Following 200 μl in duplicate were pipetted into a 96-well-cellstar plate and incubated 
at 37°C. Master mix with lysis buffer was set as blank. AFC-release was measured in 
5 minute intervals and stopped after 2 h. 
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Caspase-3 assay mix 
(Volume per reaction) 
25x Reaction buffer 
(End concentration) 
25x Reaction Buffer 20 µl Pipes 250 mM 
dH2O 465 µl EDTA 50 mM 
substrate 2.5 µl Chaps 2.5 % 
Protein sample 12.5 µl DTT 125 mM 
 
 
2.2.19. Immunofluorescence staining 
Cryosections (5µm), from mouse livers, were fixed with 4% paraformaldehyde 
for 15 min and rehydrated with PBS for 15 min. All subsequent steps were carried out 
at room temperature unless otherwise indicated in a humid light tight box to prevent 
drying and fading. PBS containing 5% goat serum and 0.3% Triton was used for 
blocking for one hour followed by an overnight incubation with primary antibody in 
blocking solution at optimized dilutions at 4°C. Slides were washed with PBS for 15 
min and incubated with secondary antibody diluted 1:200 in PBS for one hour at RT. 
Nuclei were counterstained with DAPI in mounting medium. Expression was 
visualized and documented by fluorescence microscopy (Zeiss). 
For CD11b, F4/80 and Ly6G immune cells staining cryosections were fixed 
with 4% paraformaldehyde for 15 min and rehydrated with PBS (supplemented with 
0.02% sodium azide) three times for 3 min. Tissue sections were blocked with PBS-
azide containing 0.2% BSA for 5 minutes at RT. CD11b, F4/80 or Ly6G antibody 
were diluted in PBS-azide with 1% mouse serum at 1:200 dilutions. Incubation with 
primary antibody was for 45 minutes at RT in a humidified chamber. Slides were 
washed with PBS-azide and blocked once again with PBS-azide + 0.2% mouse 
serum. Secondary antibody was diluted 1:300 in PBS-azide with 1% mouse serum 
and sections were incubated for 45 minutes at same conditions as before. Stained 
sections were washed three times in PBS-azide, three times in deionized water and 
mounted with mounting medium containing DAPI.  
TUNEL (TdT-mediated dUTP nick end labelling) is an established method for 
in situ labelling of DNA strand brakes that occur early during apoptosis. Terminal 
deoxynucleotidyl transferase (TdT) is used to introduce labelled nucleotides into 
partially degraded DNA. Liver cryosections were fixed with 4% paraformaldehyde for 
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20 min and rehydrated with PBS for 30 min. Sections were treated with 3% H2O2 in 
methanol for 10 min, and then permeabilized with 0.1% Triton 100x, 0.1% Na-citrate 
for 2 min at 4°C. Slides were washed with PBS and stained with TUNEL mix (per 
section: 0.5µl enzyme, 4.5µl TUNEL dilution buffer, 45µl buffer) in humidified 
chamber overnight at 4°C. After washing with PBS stained sections were mounted 
with DAPI mounting medium or proceeded with staining for IHC.  
 
2.2.20. β-galactosidase activity staining 
Cryosections (7µm) from mouse livers were fixed with 0.5% glutaraldehyde in 
PBS supplemented with 1mM MgCl2 for 15 min at RT and then washed with PBS, 
1mM MgCl2 for approximately 15 minutes at RT. Staining was performed with staining 
solution (0.2 mg/ml x-gal, 5mM potassium ferricyanide, 5mM potassium ferrocyanide 
in PBS, 1mM MgCl2) overnight in the humid chamber at 37°C. Sections were washed 
in PBS, 1mM MgCl2, counterstained with nuclear fast red and mounted with glycerol 
gelatine. 
 
2.2.21. Immunohistochemistry 
Paraffin embedded sections were deparaffinised and rehydrated with xylene 
and decreasing percentages of ethanol. Antigen retrieval was performed by cooking 
sections in sodium citrate buffer for 6 minutes in a microwave. After cooling for 15 
minutes, sections were rinsed in running tap water and endogenous peroxidases 
were quenched for 15 minutes. Sections were washed under running water, washed 
5 minutes in PBS. Following blocking with biotin blocking reagent for 15 minutes and 
with avidin D blocking reagent for 15 minutes, sections were blocked in PBT (PBS, 
0.1% BSA, 0.2% TritonX-100) and then incubated overnight with primary antibody at 
4°C in a humid atmosphere. Slides were washed twice with PBS and secondary 
antibody was applied for 1 hour at room temperature in humidifying box, parallel the 
HRP-ABC solution was made and incubated at least 30 minutes at room temperature 
before applying to slides. Sections were rinsed twice in PBS and HRP-ABC solution 
was applied for 1 hour at room temperature in a humidified box. After washing twice 
in PBS, signal was developed with DAB and counterstained with haematoxylin. 
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Dehydrating was performed increasing percentages of ethanol and xylene, mounted 
with Roti-histokit and visualized by bright field microscopy. 
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3. Results 
3.1. Cyclin E1 deletion inhibits DEN-induced 
hepatocarcinogenesis 
The role of E-type cyclins for cell proliferation and cancer development is 
incompletely understood due to contradictory findings. On the one hand, cyclin E1 
(CcnE1) and cyclin E2 (CcnE2) are not absolutely essential for development or 
proliferation of continuously cycling cells (Geng et al., 2003) and ablation of CcnE1 or 
CcnE2 in the liver does not result in impaired hepatocyte proliferation or liver 
regeneration (Nevzorova et al., 2009). On the other hand, CcnE1 is overexpressed in 
various tumors including hepatocellular carcinoma (HCC) and correlates with poor 
prognosis of those patients (Jung et al., 2001). 
To further evaluate the function of E-type cyclins for hepatocarcinogenesis, 
liver tumors were induced in CcnE1-/-, CcnE2-/- and wild type (WT) mice by a single 
injection of diethylnitrosamine (DEN) at two weeks of age (Vesselinovitch, 1980). In 
agreement with earlier studies (McClain et al., 2001), 95% of WT mice (21/22) 
developed macroscopically visible tumor nodules 38 weeks after DEN treatment 
(Figure 3.1A, upper panel and Figure 3.1B) with an average number of 36 tumors  
(± 6) per liver. Similarly, 100% of DEN-treated CcnE2-/- mice (19/19) revealed HCC at 
the age of 40 weeks with an average of 40 tumors per liver and median tumor 
diameter of 7 mm (± 3 mm, Figure 3.1A, medium panel and Figure 3.1B). In sharp 
contrast, CcnE1-/- mice were highly protected from DEN-mediated 
hepatocarcinogenesis. Tumor initiation and tumor progression were strongly inhibited 
by ablation of CcnE1. Only 50% (8/16) of CcnE1-/- animals developed liver tumors at 
all with low average frequency (3 tumors per liver, Figure 3.1A, lower panel and 
Figure 3.1B) and size (diameter of 2mm  ± 1 mm), compared to WT or CcnE2-/- mice 
(Figure 3.1C). In agreement with strongly decreased tumor burden in DEN-treated 
CcnE1-/- mice, the liver mass index in these mice at the age of 40 weeks was normal 
(approximately 5% ± 1%) (Figure 3.1D) compared to healthy WT mice (Nevzorova et 
al., 2009). In contrast, WT and CcnE2-/- mice showed strongly increased liver mass 
index (9% ± 5%) which served as an additional proof for massive tumor load in these 
animals.  
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Figure 3.1 Deletion of CcnE1 inhibits DEN-induced hepatocarcinogenesis. WT (n=22), CcnE1
-/-
 
(n=16) and CcnE2
-/-
 (n=19) male mice at the age of 14 days were treated once with DEN (25mg/kg 
i.p.). Animals were sacrificed at the age of 40 weeks and analysed for markers of hepatocellular 
carcinoma. (A) Macroscopic appearance of representative 40 week old livers and tumors derived from 
WT, CcnE2
-/-
 and CcnE1
-/-
 mice. Tumor burden for each individual mouse was characterized by 
analysing total number of visible tumors per mouse (B) and maximal tumor size per mouse (C). 
(D) Liver/body weight ratio in DEN-treated WT, CcnE2
-/-
 and CcnE1
-/-
 mice at the age of 40 weeks.  
*: p<0.05; **: p<0.005; ***: p<0.0005. 
 
These initial results indicate that CcnE1 is essential for DEN-induced 
hepatocarcinogenesis, whereas ablation of CcnE2 does not affect tumor initiation or 
tumor progression. 
Histologically, WT and CcnE2-/- liver sections of 40 week old DEN-treated 
animals revealed strong dysplasia and abnormal tissue architecture, whereas  
CcnE1-/- liver sections appeared mostly normal with infrequent small tumor lesions 
(Figure 3.2A), which was in good agreement with the macroscopic liver phenotype. 
The proliferating cell nuclear antigen (PCNA) is a key factor for onset of DNA 
synthesis and thus an established marker for cell proliferation. Immunostaining of 
randomly selected liver sections from DEN-treated WT and CcnE2-/- mice revealed 
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many proliferating cell PCNA positive hepatocytes hinting at excessive cell 
proliferation, which was much less evident in CcnE1-/- livers (Figure 3.2B). 
 
Figure 3.2 Decreased S-phase entry of CcnE1
-/-
 liver tumor cells at 40 weeks. (A) Haematoxylin 
and eosin (H&E) staining of paraffin embedded tissue sections of mice treated as above. Tumor areas 
are highlighted with dotted line. Original magnification: 100x. (B) PCNA expression in liver samples 
was determined by immunohistochemistry. Positive PCNA expression is stained in brown and 
highlighted by arrows. Original magnification: 200x.  
 
Figure 3.3 Liver injury marker ALT correlates with tumor number and size. (A) Serum alanine-
aminotransferase (ALT) levels in DEN-treated mice at the age of 40 weeks. (B-C) Correlation analysis 
of tumor number or tumor size with ALT. WT, CcnE1
-/-
 and CcnE2
-/-
 animals 40 weeks after DEN-
treatment were included in the analysis; animals were not differentiated by genotype. 
 
Alanine-aminotransferase (ALT) is a liver enzyme used as a standard indicator 
for liver injury. In 40 weeks old DEN-treated WT and CcnE2-/- mice ALT levels were 
slightly increased with an average of 100 U/L although with vast oscillations (Figure 
3.3A). In contrast, ALT values were significantly lower in CcnE1-/- animals and similar 
to levels of healthy untreated mice (Figure 3.3A). Interestingly, this study also 
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revealed that ALT levels positively correlate with tumor number and tumor size as 
shown in Figure 3.3B-C. 
 To determine a potential role of CcnE1 or CcnE2 in early tumor development, 
cohorts of WT, CcnE1-/- and CcnE2-/- mice were treated with DEN as before but 
sacrificed already at the age of 24 weeks. At this time point, small tumor nodules and 
liver lesions were macroscopically visible in 40% (7/15) of WT and in 47% (8/17) of  
 
Figure 3.4 Early inhibition of DEN-induced hepatocarcinogenesis in CcnE1
-/-
 mice. WT (n=15), 
CcnE1
-/-
 (n=15) and CcnE2
-/-
 (n=17) male mice were treated once with DEN (25mg/kg i.p.) at the age 
of 14 days. At the age of 24 weeks, animals were sacrificed and analysed for markers of 
hepatocellular carcinoma. (A) Macroscopic appearance of representative 24 week old livers and 
tumors derived from WT, CcnE2
-/-
 and CcnE1
-/-
 mice. (B) Tumor frequency of mice at the age of 24 
weeks, the values represent the percentage of mice with macroscopic visible tumors (tumor size 0.5 – 
2 mm in diameter). (C) Liver/body weight ratio in DEN-treated WT, CcnE2
-/-
 and CcnE1
-/-
 mice at the 
age of 24 weeks. (D) Serum ALT levels in DEN-treated mice at the age of 24 weeks. 
 
CcnE2-/- mice, whereas all CcnE1-deficient animals (n=15) revealed normal liver 
morphology without visible tumor nodules (Figure 4A-B). However, no differences in 
liver mass index (Figure 3.4C) or ALT values (Figure 3.4D) were observed between 
the groups which rather reflects the early stage of tumor development in this 
experiment.  
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Histologically, dysplastic lesions were clearly detectable in WT and CcnE2-/- 
livers at this age and comprised 1.65% and 2.63% of total tissue area, respectively 
(Figure 3.5A). In contrast, only approximately 0.31% of liver tissue was considered 
dysplastic in DEN-treated CcnE1-/- mice at this age (Figure 3.5A). In line with these 
findings, PCNA expression was elevated in WT and CcnE2-/- livers as measured by 
immunostaining, which was not evident in CcnE1-/- mice (Figure 3.5B). These results 
demonstrate that ablation of CcnE1 is already protective in an early state of tumor 
development in the liver. 
Overexpression of E-type cyclins is a hallmark of many human cancers 
including breast cancer and hepatocellular carcinoma (Caldon and Musgrove, 2010). 
To determine if this is also true in the DEN-model in mice, mRNA levels of CcnE1, 
CcnE2 and its downstream target CcnA2 were measured where applicable in DEN-
induced liver tumors and compared to basal expression in untreated mice. CcnE1 
mRNA expression was not changed at early stage of tumor development in the 
cohorts at the age of 24 weeks in comparison to untreated controls. In contrast, 
CcnE1 mRNA was significantly upregulated in tumor nodes of DEN-treated livers at 
the age of 40 weeks (Figure 3.6A), corroborating the findings in human HCC studies. 
This result validates the relevance of CcnE1 overexpression in DEN-induced 
hepatocarcinogenesis in mice designating the importance in advanced tumor 
development. Interestingly, CcnE2 mRNA was markedly downregulated in livers of 
DEN-treated CcnE1-/- mice at the age of 40 weeks (Figure 3.6B) suggesting that 
tumor resistance is related to overall low CcnE expression levels.  
Cyclin A2 (CcnA2) is a promoter of S-phase progression. To determine if 
reduced tumor susceptibility in CcnE1-/- mice is associated with diminished DNA 
replication, CcnA2 mRNA expression was also evaluated in DEN-treated WT,  
CcnE1-/- and CcnE2-/- mice (Figure 3.6C). No differences in CcnA2 expression were 
observed between the cohorts at the age of 24 weeks, indicating that the impact of 
DNA synthesis is minor during early liver tumorigenesis. 
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Figure 3.5 Decreased S-phase entry of CcnE1
-/-
 liver tumor cells at 24 weeks. (A) H&E staining of 
paraffin embedded tissue sections of DEN-treated mice at the age of 24 weeks. Tumor areas are 
highlighted with dotted line (upper panel and lower panel left). Original magnification: 100x. Tumor 
area in tissue sections (lower panel right). Tumor area represents surface size occupied with tumors 
visible in H&E stained sections and compared to the whole section size. *: p<0.05. (B) PCNA 
expression in liver samples was determined by immunohistochemistry. PCNA positive liver cells are 
stained in brown and are highlighted by arrows; 24 week old DEN treated animals (upper panel) are 
compared to untreated controls (lower panel). Original magnification: 200x. 
 
However, at the age of 40 weeks liver samples from WT and CcnE2-/- mice revealed 
significantly increased CcnA2 expression. In contrast, under these conditions CcnA2 
was only expressed at baseline level in CcnE1-/- livers (Figure 3.6C). Thus, CcnE1 
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but not CcnE2 is required for driving CcnA2 and DNA replication during tumor 
progression in the liver.  
 
Figure 3.6 Effects of 
CcnE1 on overall cyclin 
gene expression in DEN 
induced hepatocarcinoge-
nesis. mRNA expression 
was measured by real-Time 
PCR analysis in untreated 
control, 24 week and 40 
week liver and liver tumor 
tissue for WT (white bars), 
CcnE1
-/-
 (grey bars) and  
CcnE2
-/-
 (black bars) mice 
treated as described in 
figures 3.1 and 3.4  (A) 
CcnE1 mRNA, (B) CcnE2 
mRNA, (C) CcnA2 mRNA 
expression. Indicated gene 
expression levels were 
normalized to expression of 
the housekeeping gene 
GAPDH and calculated as 
fold induction in comparison 
to untreated controls. Each 
bar represents a value of 
minimum 4-6 animals, data 
are presented as the 
average ± s.d. *: p<0.05; **: 
p<0.005; ***: p<0.0005. 
 
 
 
 
 
 
Replicative senescence is a natural barrier to clonal expansion of tumor cells 
which plays a vital part in limiting tumorigenesis (Mooi and Peeper, 2006; Prieur and 
Peeper, 2008) and is in part controlled by cell cycle inhibitors p16 and p21 (Lin et al., 
1996; Palmero et al., 1997). To determine if tumor resistance in CcnE1-/- livers is 
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related to increased induction of senescence, senescence associated  
β-galactosidase (SA-β-gal) activity was examined in liver sections from WT, CcnE1-/- 
and CcnE2-/- mice at several time points after DEN treatment. Indeed, CcnE1-/- livers 
showed increased SA-β-gal activity compared to WT and CcnE2-/- counterparts 40 
weeks after DEN treatment (Figure 3.7A). However, this effect was independent of 
p16, which was markedly upregulated during tumorigenesis in all investigated 
cohorts to the same extend (Figure 3.7B). Accordingly, tumor suppression in CcnE1-/- 
mice is associated with p16-independent replicative senescence. 
 
Figure 3.7 Tumor suppression in CcnE1
-/- 
is associated with senescence. (A) Cryosections of 
DEN treated livers as described in figures 3.1 and 3.4, of the indicated genotypes at the age of 24 and 
40 weeks were stained for SA-β-galactosidase activity, positive cells are stained with blue. Scale bar = 
10 µm. (B) p16 mRNA expression in untreated control, 24 week and 40 week liver tissue for WT (white 
bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) animals. Expression levels were normalized to 
expression of the housekeeping gene GAPDH and calculated as fold induction in comparison to 
untreated controls. Each bar represents a value of minimum 4-6 animals, data are presented as the 
average ± s.d. 
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3.2. Analysis of the immediate response after DEN-induced 
acute liver injury 
The previous experiment clearly indicated that depletion of CcnE1 inhibits both 
tumor initiation and tumor progression upon DEN treatment. In order to investigate 
the mechanism by which CcnE1 triggers tumor initiation, the immediate response 
after acute DEN treatment regarding liver regeneration and cell cycle regulation were 
addressed in detail. Besides its mutagenic properties, DEN has the potential to 
induce toxic acute liver injury which is associated with centrolobular necrosis and 
apoptosis (Karin and Greten, 2005). The liver has a unique property to regenerate 
after surgical resection or toxic injury through proliferation of fully differentiated 
quiescent hepatocytes and biliary epithelial cells (Fabrikant, 1968; Grisham, 1962). 
Thus it was anticipated that following acute DEN-treatment, the injured liver would be 
regenerated by proliferating hepatocytes carrying malignant mutations, which 
potentially could be CcnE1-dependent. To test this hypothesis, 6-8 weeks old male 
WT, CcnE1-/- and CcnE2-/- mice were injected with a single high dose of DEN (200 
mg/kg) to induce acute liver injury and analyzed for the acute response regarding 
liver injury, regeneration and cell cycle progression in a time frame of 0-196 hours 
post treatment.  
 
3.2.1. Ablation of CcnE1 or CcnE2 does not result in alterations of DEN- 
induced liver necrosis and apoptosis 
Following induction of DEN-mediated acute liver injury in CcnE1-/-, CcnE2-/- 
and WT mice, the kinetics and strength of tissue damage was monitored by 
measurement of the circulating liver enzyme ALT from blood samples showing 
maximal induction 48 h after treatment, which was independent of CcnE1 or CcnE2 
expression, respectively (Figure 3.8A). In agreement with these findings, histological 
analysis of H&E stained liver sections revealed large necrotic areas mostly situated 
around the central veins, which were of similar size in animals of all three genotypes 
(Figure 3.8B upper panel).  
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Figure 3.8 DEN treatment induces elevated apoptosis in DEN acute liver injury model. Male 
mice 6-8 weeks of age were injected with DEN (200 mg/kg i.p.) to induce acute liver injury, livers were 
investigated up to 240 hours after injection. (A) Serum level of alanine-aminotransferase (ALT) of mice 
at indicated time points after DEN injection. Each bar represents a value of minimum 3 animals, data 
are presented as the average ± s.d. (B) H&E staining of paraffin embedded liver sections (top panel), 
apoptosis/necrosis areas are highlighted with dotted line. Original magnification: 100x. TUNEL staining 
on frozen liver sections (bottom panel). TUNEL positive cells are green, nuclei are visualized by DAPI: 
blue. Scale bar: 100 µm. (C) Caspase-3 activity was measured by assay for specific caspase-3 
substrate turnover and calculated as fold induction in comparison to untreated livers. Data are 
presented as comparison of CcnE1
-/-
 (squares) to WT (circles) animals in the left graph and 
comparison of CcnE2
-/-
 (triangles) to WT (circles) animals in the right graph. Each value represents a 
minimum of 3 animals; data are presented as the average ± s.d. 
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Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL assay) 
is an established method for detecting DNA fragmentation that occurs after apoptotic 
signaling. Liver cryosections from DEN-treated CcnE1-/-, CcnE2-/- and WT mice 
revealed strongly elevated numbers of TUNEL-positive cells 48 hours after treatment 
(Figure 3.8B, lower panel) and the staining pattern correlated with the foci of 
centrolobular tissue damage (compare Figure 3.8B upper panel). However, in some 
cases TUNEL staining may also label necrotic cells. To clearly distinguish apoptotic 
cell death from necrosis, the enzymatic activity of caspase-3 was determined after 
DEN treatment. Caspase-3 is an executioner caspase, which acts downstream of 
intrinsic and extrinsic apoptotic signaling pathways. Therefore, caspase-3 activation 
is a highly specific indicator of apoptosis. Caspase-3 was transiently activated 48 
hours after DEN treatment in   CcnE1-/-, CcnE2-/- and WT mice (Figure 3.8C). 
Interestingly, at this time point caspase-3 activity was slightly higher in CcnE1-/- livers 
compared to WT and CcnE2-/- mice, although these differences were not significant. 
These data suggested that DEN induced the same degree of acute liver injury in 
CcnE-deficient mice and controls. 
The role of pro-apoptotic signals for tumor initiation is still under discussion. 
Apoptosis is an important mechanism for eliminating transformed cells (Eferl et al., 
2003; Maeda et al., 2005), whereas elevated apoptotic cell death may also induce 
compensatory proliferation and thus tumorigenesis (Liedtke et al., 2011). CcnE1-/- 
mice revealed faintly increased apoptosis after acute DEN treatment and reduced 
tumor incidence as long term effect hinting at a correlation between tumor resistance 
and apoptosis-sensitivity of CcnE1-/- mice. To clarify this aspect, the mRNA 
expression of several key players involved in apoptosis induction was investigated by 
quantitative real-time PCR (Figure 3.9). Given that DEN-induced DNA damage would 
predominantly induce intrinsic apoptosis pathways, the gene expression levels of 
proapoptotic Bcl-2 family members (bax, bcl6, bim, bNIP3, noxa, puma in Figure 
3.9A-F) and antiapoptotic Bcl-2 family members (bcl-2, bcl-xl in Figure 3.9G-H) were 
analyzed. Liver tissue damage may also induce inflammation and infiltration of 
immune cells, which eventually could promote extrinsic apoptotic pathways. 
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Figure 3.9 Mediators of intrinsic and extrinsic apoptosis are elevated. mRNA expression for 
indicated genes were quantified by Real-Time PCR in livers at timepoints: 0, 24, 48, 72, 96, 168 and 
240 hours after DEN injection (200mg/kg i.p.) for WT (white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 
(black bars) livers. Expression levels were normalized to expression of the housekeeping gene 
GAPDH and calculated as fold induction in comparison to untreated controls. Each bar represents a 
value of minimum 3 animals; data are presented as the average ± s.d. 
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Therefore the expression of death receptors and their cognate ligands (TRAIL, FasL, 
CD95) were also analyzed (Figure 3.9I-J). Except for FasL (which will be discussed 
in chapter 3.2.2), the expression levels of the analyzed apoptotic genes were 
upregulated after DEN administration, but not significantly different between the 
genotypes. In conclusion from these results, CcnE1 does not regulate the main 
modulators of apoptosis; consequently, inhibition of tumorigenesis as observed in 
CcnE1-/- mice cannot be explained by increased apoptosis of malignant transformed 
hepatocytes. 
 
3.2.2. DEN induces differential immune response in CcnE1-/- and  
CcnE2-/- livers 
Hepatic cell death has the ability to induce an immune response in the liver. 
Dying hepatocytes release signals that are capable of activating the resident 
macrophages of the liver (Kupffer cells), natural killer cells or natural killer T cells. 
These cells potentially secrete pro-inflammatory cytokines (e.g. TNF, IL-6, Fas) or 
hepatoprotective mediators (e.g. IL-10, Prostaglandins) that determine the 
regenerative response to drug induced liver injury (Holt and Ju, 2006). 
A recent study demonstrated an essential tumor promoting role of the cytokine 
IL-6 in the DEN model in mice (Naugler et al., 2007). To determine, if the reduced 
tumor susceptibility of CcnE1-/- mice is associated with altered IL-6 response, the 
levels of IL-6 mRNA in CcnE1-/-, CcnE2-/- and WT mice were measured by 
quantitative Real-Time PCR at distinct time points after acute DEN treatment. WT 
mice showed elevated IL-6 levels beginning 48 h after DEN-treatment with maximal 
expression after 96 h (Figure 3.10A). Interestingly, CcnE1-/- mice revealed only a 
transient IL-6 response, which was restricted to 48 h post treatment (Figure 3.10A). 
Thus, ablation of CcnE1 seems to affect the activation or proliferation of IL-6 
expressing cells such as macrophages. In sharp contrast, CcnE2-/- mice showed an 
overall increased IL-6 expression compared to WT and CcnE1-/- mice (Figure 3.10B). 
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Figure 3.10 Loss of CcnE1 is associated with attenuated immune response to DEN induced 
liver injury. mRNA expression of IL-6 (A-B) and FasL (C-D) in liver tissue up to 240 hours after DEN. 
Expression levels were normalized to expression of the housekeeping gene GAPDH and calculated as 
fold induction in comparison to untreated controls. Data are presented as comparison of CcnE1
-/-
 
(squares, full line) to WT (circles, discontinued line) animals in (A, C) and comparison of CcnE2
-/-
 
(triangles, full line) to WT (circles, discontinued line) animals in (B, D). Each value represents a 
minimum of 3 animals, data are presented as the average ± s.d. *: p<0.05; **: p<0.005 (E) 
Immunofluorescence analysis of liver macrophages with anti-F4/80 (upper panel) and infiltrating 
Results 
58 
 
immune cells with anti-CD11b (middle panel) or anti-Ly6G (bottom panel) 48 hours after induction of 
acute liver injury by DEN (200mg/kg i.p.). F4/80, CD11b and Ly6G positive cells are stained green, 
nuclei stained with DAPI are blue. Scale bar = 100 µm. 
 
As these mice also show overexpression of CcnE1 (compare Figure 3.11C) 
these data suggests that the CcnE1 expression levels are associated with the 
strength of the IL-6 response. Similar expression patterns were observed for FasL 
mRNA showing an overall reduced and transient induction in CcnE1-/- mice (Figure 
3.10C) and substantial stronger expression in CcnE2-/- animals (Figure 3.10D). To 
identify the IL-6 and/or FasL expressing immune cells, DEN-treated livers were 
stained for F4/80, Cd11b and Ly6G (Figure 3.10E). F4/80 is a cell surface marker for 
murine macrophages (Leenen et al., 1994) and Cd11b is expressed on the surface of 
monocytes, granulocytes, macrophages and natural killer cells (Solovjov et al., 
2005). Granulocytes, neutrophils and eosinophils are characterized surface 
expression of Ly6G (Fleming et al., 1993). Of interest, F4/80 positive liver 
macrophages were diminished in CcnE1-/- mice 48 h after DEN treatment in 
comparison to WT or CcnE2-/- mice (Figure 3.10E, upper panel). As Kupffer cells 
contribute to hepatocarcinogenesis e.g. by expression of IL-6 or generation of 
superoxide (Teufelhofer et al., 2005), these data implicates that impaired survival or 
activation of CcnE1-deficient Kupffer cells may contribute to inhibition of tumor 
initiation in the liver. In contrast to these findings, Cd11b and Ly6G positive cells 
were detectable in the liver starting at 48 hours post treatment without significant 
differences between the genotypes (Figure 3.10E, middle and lower panel 
respectively).  
 
3.2.3. CcnE1 deficiency results in prolonged cell cycle arrest after DEN 
induced toxic liver injury 
Following liver injury, the liver has the capacity to repair tissue damage by 
compensatory proliferation of surviving hepatocytes. In the DEN model, 
compensatory proliferation is also essential for the genetic manifestation of malignant 
mutations and thus tumor initiation. To investigate the role of CcnE1 and CcnE2 for 
compensatory proliferation after genotoxic liver damage, expression of the 
proliferation marker Ki67 was determined by immunofluorescence staining.  
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Figure 3.11 Ablation of CcnE1 correlates with prolonged cell cycle arrest after DEN induced 
damage. Cell cycle kinetics was investigated in mice treated with DEN (200mg/kg i.p.) up to 240 hours 
after injection.  (A) Ki67 immunostaining of liver cryosections from WT, CcnE1
-/-
 and CcnE2
-/-
 animals 
48 hours after DEN. Ki67 positive cells are stained green, nuclei are stained with DAPI (blue). Scale 
bar: 50 µm. (B) Quantification of Ki67 positive cells relative to total nuclei per power field. The amount 
of Ki67 positive cells was determined by counting at least 4 representative high power fields per 
mouse. Data are presented as comparison of CcnE1
-/-
 (squares, full line) to WT (circles, discontinued 
line) animals in the left graph and comparison of CcnE2
-/-
 (triangles, full line) to WT (circles, 
discontinued line) animals in the right graph. Each value represents a minimum of 3 animals, data are 
presented as the average ± s.d. ***: p<0.0005. (C) CcnE1 mRNA expression quantified by real-Time 
PCR in livers at 0-168 hours after DEN injection for WT (white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 
(black bars) livers. Expression levels were normalized to expression of the housekeeping gene 
GAPDH and calculated as fold induction in comparison to untreated controls. Each bar represents the 
mean of at least 3 animals, data are presented as the average ± s.d. *: p<0.05; 
#
: p<0.0005. 
 
In WT and CcnE2-/- mice, elevated hepatocyte proliferation was first detectable 
48 h post treatment (Figure 3.11A-B), In contrast, increased proliferation in CcnE1-/- 
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livers was first detectable after 10 days but remained at baseline levels from 48-168 
h after DEN stimulation. These results indicate that CcnE1 is essential for immediate 
cell cycle activation after toxic liver injury. In agreement with these findings, CcnE1 
levels are usually increased in irradiated cells or following treatment with 
chemotherapeutics (Blattner et al., 1999; Mazumder et al., 2007). To further 
determine the regulation of CcnE1 in liver cells after DEN-induced genotoxic injury, 
CcnE1 mRNA expression was measured in WT, CcnE1-/- and CcnE2-/- mice. CcnE1 
was highly induced in WT livers after DEN genotoxic injury and interestingly, further 
upregulated in CcnE2-/- livers (Figure 3.11C). Hence, CcnE1 is a highly responsive 
gene to genotoxic stress. This was also true for the G1-cyclins CcnD1, CcnE2 and 
CcnA2 and the downstream transcription factors E2F1 and E2F2 which were also 
induced by DEN although without significant differences between the genotypes 
(Figure 3.12). 
To elucidate the mediators of cell cycle arrest in CcnE1-/- mice, the regulation 
of the cell cycle inhibitors p21 and p27 was intensively investigated as these Cdk 
inhibitors are known to negatively regulate cell cycle progression at G1 (Polyak et al., 
1994a; Polyak et al., 1994b; Toyoshima and Hunter, 1994). The p21 protein inhibits 
cyclin-dependent kinases and proliferating-cell nuclear antigen (PCNA) that are both 
required for cell cycle transition. The p21 gene is under transcriptional control of p53, 
indicating a role of p21 for p53-dependent cell cycle arrest. DEN induced an 
immediate and strong induction of p21 mRNA (approximately 40-50 fold) within 24 
hours, which was similar in WT, CcnE1-/- and CcnE2-/- mice (Figure 3.13A, upper 
panel). However, 48-96 h after DEN treatment, increased p21 mRNA expression was 
evident in CcnE1-/- mice compared to WT and CcnE2-/- mice. More importantly, 
between 48-96 h post treatment, p21 protein levels CcnE1-/- liver were increased 
compared to both WT and CcnE2-/- mice (Figure 3.13A, lower panel). These data 
strongly suggests that the prolonged cell cycle arrest observed in CcnE1-/- mice is at 
least in part mediated through increased p21 gene expression and prolonged p21 
protein stability. 
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Figure 3.12 Cell cycle regulating genes are induced after DEN application. mRNA of cell cycle 
regulators (CcnE2, CcnA2, CcnD1 and transcription factors E2F1, E2F2) were quantified by Real-
Time PCR in livers at 0, 24, 48, 72, 96, 168 and 240 hours after DEN injection (200mg/kg i.p.) for WT 
(white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) livers. Expression levels were normalized 
to expression of the housekeeping gene GAPDH and calculated as fold induction in comparison to 
untreated controls. Each bar represents a value of minimum 3 animals, data are presented as the 
average ± s.d 
 
The p27 protein binds and thereby inactivates Cdk2-CcnE or Cdk2-CcnA 
complexes resulting in cell cycle arrest. Activity of p27 is regulated through 
transcriptional, translational and post-translational mechanisms (Lee and Kim, 2009). 
Following DEN treatment, p27 gene expression was not substantially induced in any 
of the investigated genotypes as demonstrated by quantitative Real-Time PCR 
(Figure 3.13B, upper panel). However, increased levels of p27 protein were observed 
in   CcnE1-/- livers 72-96 hours after DEN genotoxic injury (Figure 3.13B lower panel) 
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suggesting that ablation of CcnE1 does not affect transcriptional control of p27 but 
increases the stability of the p27 protein. Taken together, these observations strongly 
suggest that p21 and p27 synergistically promote cell cycle arrest in CcnE1-/- livers 
after DEN-induced damage. 
 
 
Figure 3.13 Cell cycle inhibitors are aberrantly elevated in CcnE1-deficient animals after DEN 
application. (A) p21 mRNA expression and western blot analysis of p21 protein in WT (white bars), 
CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) mice. (B) p27 mRNA expression and western blot 
analysis of p27 protein in WT (white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) mice. mRNA 
expression levels were normalized to expression of the housekeeping gene GAPDH and calculated as 
fold induction in comparison to untreated controls. Each bar represents a value of minimum 3 animals; 
data are presented as the average ± s.d. For protein expression detected by western blot, GAPDH 
was used as equal loading control. 
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Several studies proved that p21 is not only a cyclin/Cdk inhibitor, but can also 
interact with diverse proteins involved in replication, proliferation, DNA damage and 
apoptosis (Child and Mann, 2006). To mechanistically explain the prolonged cell 
cycle arrest and impaired tumor initiation in CcnE1-/- mice after DEN treatment, it was 
speculated that p21 may form alternate protein complexes in the absence of CcnE1 
triggering tumor-suppressive effects e.g. via cell cycle arrest and improved DNA 
repair. To test this hypothesis, complex formation of p21 in CcnE1-/- livers was 
investigated by a combination of immunoprecipitation experiments and a proteomics 
approach. 
WT, CcnE1-/- and CcnE2-/- mice were treated with a high dose of DEN and 
sacrificed at distinct time points between 0-168 h post treatment. p21 protein 
complexes from livers were purified by immunoprecipitation and analyzed on a SDS 
PAGE by silver staining (sensitivity: 1-5 ng). Interestingly, several p21-interacting 
proteins with a molecular weight of approximately 40 and 260 kD were detected in 
cell cycle arrested CcnE1-/- livers (48-96 h after DEN treatment, Figure 3.14A, also 
compare Figure 3.11B). In contrast, these proteins were absent or barely visible in 
WT or CcnE2-/- samples (Figure 3.14A).  
As these p21-interacting proteins were potential mediators of the observed 
tumor-suppressive effects it was next aimed to identify these factors by a proteomics 
approach with a kind support of Dr. Corinna Henkel (Department of Pathology, 
University Hospital Aachen). Immunoprecipitated p21 complexes isolated from WT 
and CcnE1-/- mice 48 hours after DEN treatment were analyzed by Two-dimensional 
difference in gel electrophoresis (2D DIGE), separating the proteins by mass and by 
isoelectric focusing. Genotype-specific visualization of interacting proteins revealed 
overall more p21 interaction partners and stronger complex formation in CcnE1-/- 
livers after DEN-treatment (Figure 3.14B, upper panel) compared to WT mice. In 
addition, a multiplicity of proteins were upregulated in CcnE1-/- liver (Figure 3.14B, 
lower panel) thereby confirming the increased presence of p21 in these samples as 
demonstrated in Figure 3.13A. Unfortunately, identification of representative proteins 
which selectively interacted with p21 in CcnE1-/- liver using mass spectrometry was 
not successful due to limited amounts of purified protein complexes. However, these 
data strongly suggests that ablation of CcnE1 triggers the prolonged formation of 
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aberrant p21 complexes potentially contributing cell cycle arrest or tumor 
suppression.  
 
Figure 3.14 Differential complex formation of p21 in WT and CcnE1
-/- 
mice after DEN induced 
damage. (A) Immunoprecipitated complexes with p21 were isolated from WT, CcnE1
-/-
 and CcnE2
-/-
 
livers treated with DEN (200mg/kg) and analysed on PAGE after silver staining. (B) 2D gel 
electrophoresis, 2D DiGE (two-dimensional difference in gel electrophoresis) experiment comparing 
the p21 complexes of WT (417; cy3) and CcnE1
-/-
 (2026; cy5) DEN-treated animals at 48 hour time 
point including overlay (yellow signal = overlay) indicates common protein expression in WT and 
CcnE1
-/-
 sample (upper panel). Images were analysed with Decyder 5.01 (DIA Modul), up-regulated 
spots (blue), no difference (green) and downregulated spots (red) in CcnE1
-/-
 compared to WT (lower 
panel). 
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3.2.4. Ablation of CcnE1 triggers prolonged p53-checkpoint activation 
after DEN-induced DNA damage  
DEN is a genotoxic agent, which induces DNA damage such as DNA adducts. 
In addition, overexpression of CcnE1 has also been shown to induce DNA damage at 
least in vitro, which can activate a p53-dependent checkpoint (Bartkova et al., 2006; 
Loeb et al., 2005; Spruck et al., 1999). It was therefore speculated that ablation of 
CcnE1 might directly affect the strength of DNA damage after genotoxic liver injury or 
modulate the extent of DNA damage response (DDR) to DEN e.g. via p53-dependent 
pathways.  
To quantify the extent of DNA damage response (DDR) to DEN in CcnE 
knockout mice, the levels of Ser139 phosphorylated histone variant H2A.X (γH2AX) 
was determined which served as a marker for DNA double strand breaks. H2A.X 
phosphorylation was verified by immunofluorescent staining of liver cryosections and 
through western blot analysis in WT, CcnE1-/- and CcnE2-/- mice after DEN treatment 
(Figure 3.15A-B). These data hinted at a prolonged persistence of damaged DNA in 
DEN-treated CcnE2-/- livers (24-72 h post DEN) and overall reduced DNA damage in 
CcnE1-/- mice 24-48 h after treatment (Figure 3.15B).  
Another mode of DNA damage is the generation of abasic 
(apurinic/apyrimidinic; AP) sites, which are also promoted by genotoxic agents or 
appear as intermediates during nucleotide excision repair (NER). Unrepaired AP 
sites inhibit topoisomerases, replication and transcription and can be mutagenic 
(Dahlmann et al., 2009). The presence of AP sites in WT, CcnE1-/- and CcnE2-/- mice 
at distinct time points after DEN-treatment was quantified using a commercial assay 
(Figure 3.15C). Although the data clearly demonstrated that DEN generated AP sites 
in the liver, significant differences between the groups were not evident. Thus, CcnE1 
is most likely not involved in NER. However, hepatic ablation of CcnE1 may result in 
reduced formation or accelerated procession of DSB. 
DNA damage induces phosphorylation of p53 at several residues including 
Ser15 (Pluquet and Hainaut, 2001). Phosphorylation at Ser15 reduces the interaction 
between p53 and its negative regulator Mdm2, promoting accumulation and 
activation of p53. Ser15 phosphorylation of p53 is mediated by ATM, ATR and DNA-
PK (Meek and Anderson, 2009). Interestingly, p53 phosphorylation in CcnE1-
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deficient livers was stronger and substantially prolonged upon DEN challenge in 
comparison to WT and CcnE2-/- mice, (Figure 3.15D, upper panel). These findings 
are consistent with the expression levels of the p53 downstream target p21 (compare 
Figure 3.13A) and would explain the prolonged cell cycle arrest of CcnE1-/- 
hepatocytes as a consequence of prolonged p53-dependent checkpoint activation. 
However, the precise mechanism of p53 modulation by CcnE1 remains to be 
elucidated.  
A variety of stress signals can activate c-Jun N-terminal kinases (JNK) via 
phosphorylation. Activated JNKs modify the activity of several proteins involved in 
cell growth, differentiation, survival and apoptosis (Vlahopoulos and Zoumpourlis, 
2004). Of notice, p53 is also a substrate of JNK (Fuchs et al., 1998a). Accordingly, it 
was investigated if JNK (JNK1 and JNK2 proteins) are activated in response to DEN. 
Western blot analysis revealed increased phosphorylation of JNK1/2 in CcnE1-/- mice 
at critical time points after DEN application (48-72 h post DEN with maximal liver 
injury and cell cycle arrest) in comparison to WT and CcnE2-/- mice (Figure 3.15D, 
lower panel).  
To further evaluate the role of DDR signals for preventing tumorigenesis in 
CcnE1-/- livers, the expression of selected genes potentially involved in this pathway 
was determined by quantitative Real-Time PCR (Figure 3.16). These gene sets 
involved DNA damage indicators (p53, Mdm2, Gadd45αin Figure 3.16A-C), 
members of oxidative stress pathway (Cat, MnSOD in Figure 3.16D-E), and 
chromatin remodelling factors (Smarcc1/BAF155), Smarca4/BRG1 in Figure  
3.16F-G). Out of these genes, only p53, Mdm2 and Gadd45 mRNA levels were 
substantially induced after DEN application, although without significant differences 
between WT, CcnE1-/- and CcnE2-/- animals. 
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Figure 3.15 Loss of CcnE1 allows prolonged p53 checkpoint and JNK activation. Male mice 6-8 
weeks of age were injected with DEN (200 mg/kg i.p.) to induce acute liver injury as before, livers were 
investigated for DNA damage response and stress markers up to 168 or 240 hours after injection. (A) 
Phosphorylation of H2AX on Ser139 (γH2AX) was stained on liver cryosections from WT, CcnE1
-/-
 and 
CcnE2
-/-
 animals 48 hours after DEN. γH2AX positive cells are stained red, nuclei are stained with 
DAPI: blue. Scale bar: 50 µm. (B) γH2AX was visualised by western blot analyses for WT, CcnE1
-/-
 
and CcnE2
-/-
 liver tissues up to 168 hours after DEN application. GAPDH was used as equal loading 
control. (C) Abasic sites (AP sites) were measured by specific ELISA for isolated genomic DNA. Data 
are displayed for WT (white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) animals at indicated 
time points after DEN. Each bar represents a value of 3 animals; data are presented as the average ± 
s.d. (D) Western blot analysis of p53 phosphorylation status at Ser15 (upper panel) and JNK1/2 
phosphorylation (lower panel) in DEN treated livers at indicated time points. GAPDH was used as 
equal loading control, note: p21 and pJNK1/2 were probed on the identical membrane, therefore the 
same GAPDH was shown in figure 3.13A and 3.15D. 
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In summary these data suggests that prolonged DNA damage response in 
CcnE1-deficient liver cells is mediated predominantly via post-translational 
mechanisms involving enhanced induction of JNK and prolonged activation of p53.  
 
Figure 3.16 Mediators of DNA damage response are induced after DEN application. 6-8 weeks 
old male mice treated as described before, livers were investigated at 0, 24, 48, 72, 96, 168 and to 
240 hours after injection for DNA damage markers: p53, GADD45α, Mdm2 (A-C); members of 
oxidative stress pathway: MnSOD, Catalase (Cat) (D-E); and chromatin remodelling members: 
Smarca4 and Smarcc1 (F-G). mRNA expression for indicated genes were quantified by real-time PCR 
for WT (white bars), CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) livers. Expression was normalized 
to the untreated control mRNA, each bar represents a value of minimum 3 animals; data are 
presented as the average ± s.d. 
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3.2.5. Ablation of CcnE1 does not induce cellular senescence in acute 
DEN-mediated liver injury 
Previous results (compare Figure 3.7A) indicated that CcnE1-deficiency was 
associated with increased cellular senescence in aged livers. Therefore it was of 
interest to test if this might also apply for acute DEN-induced liver damage as  
CcnE1-/- mice displayed prolonged cell cycle. To address this question, SA-β-
galactosidase activity was measured by staining DEN-treated livers from WT,  
CcnE1-/- and CcnE2-/- mice with x-gal. Surprisingly, elevated SA-β-galactosidase 
activity was only observed in CcnE2-/- cryosections, but not in samples from CcnE1-/- 
livers (Figure 3.17A). The underlying mechanisms could not be clarified as mRNA 
levels of senescence markers p16, p19 and fibronectin (Fb) were not significantly 
different between WT, CcnE1-/- and CcnE2-/- mice (Figure 3.17B). Thus, increased 
hepatic SA-β-gal activity in CcnE2-deleted animals after DEN administration is not 
related to induction of established senescence markers and does not explain 
prolonged cell cycle arrest in CcnE1-/- mice. However, previous studies suggested 
that massive overexpression of CcnE1 – which was also observed in CcnE2-/- liver 
(compare Figure 3.10C) – may lead to senescence (Bartkova et al., 2006).    
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Figure 3.17 Senescence in DEN induced acute liver injury is associated with absence of  
CcnE2
-/-
. 6-8 weeks old male mice treated as described before, were investigated for senescence 
markers. (A) Representative images of WT, CcnE1
-/-
 and CcnE2
-/-
 cryosections of livers isolated 72 
hours after DEN injection and stained for SA-β-galactosidase activity are presented. Positive cells are 
stained with blue, liver tissue is counterstained with nuclear fast red. Scale bar: 50 µm. (B) mRNA 
expression of p16, p19 and Fb (fibronectin) was quantified by real-time PCR for WT (white bars), 
CcnE1
-/-
 (grey bars) and CcnE2
-/-
 (black bars) animals. Expression was normalized to the untreated 
control mRNA, each bar represents a value of minimum 3 animals; data are presented as the average 
± s.d. 
 
3.3. Implementations for the acute DEN-model in juvenile mice  
The previous experiments investigated the consequences of acute DEN-
mediated liver injury in adult mice using high dosage. However, the induction of HCC 
was performed using low dosage DEN in juvenile mice at the age of 2 weeks, raising 
the question if ablation of CcnE1 comprises similar effects in juvenile versus adult 
livers. To address this point, two week old WT and CcnE1-/- mice were injected with 
low dose DEN as used for HCC induction and sacrificed 48 hours after application.  
As expected, untreated livers from juvenile mice (WT and CcnE1-/-) showed 
substantial hepatocyte proliferation as detected by immunohistochemistry with the  
S-phase marker PCNA (Figure 18A, upper panel) due to progressive liver 
development, which was a striking difference to the data obtained from adult mice. 
However, 48 h after DEN-treatment, juvenile CcnE1-/- livers showed a striking 
reduction in S-phase, which was not evident in corresponding WT mice (Figure 
3.18A, lower panel and right panel). In addition, apoptosis was slightly elevated in 
juvenile CcnE1-/- mice as assessed by TUNEL staining and immunhistochemistry 
specific for cleaved caspase-3 (Figure 3.18B-C). 
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Figure 3.18 Apoptosis and cell cycle arrest contribute to tumor suppression upon DEN 
treatment. Two week old male WT, CcnE1
-/-
 and CcnE2
-/-
 mice were treated with low dose DEN 
(25mg/kg i.p.) and sacrificed 48 hours later. Livers were analyzed for markers of apoptosis and 
proliferation. (A) PCNA immunohistochemistry of paraffin embedded sections, WT and CcnE1
-/-
 
controls (untreated two weeks old mice) were compared to 48 hour time point after DEN application. 
PCNA positive cells are stained brown. Scale bar: 50 µm. The amount of PCNA positive (PCNA+) 
cells was determined by counting at least 3 representative high power fields per mouse. Data are 
presented as comparison of WT (white bars) to CcnE1
-/-
 (grey bars) animals in the right graph. Data 
are presented as the average ± s.d. *: p<0.05, ***: p<0.0005. (B) TUNEL staining of liver cryosections. 
TUNEL positive cells are stained in green and nuclei with DAPI (blue). Scale bar: 50 µm. (C) Cleaved 
caspase-3 immunohistochemistry of paraffin embedded sections. Cleaved caspase-3 positive cells are 
stained brown and highlighted with arrows. Scale bar: 10 µm.  
 
Thus, the low dose DEN model in juvenile mice confirms the previous data 
generated from adult mice and defines CcnE1 as an essential factor for overriding 
cell cycle checkpoints after toxic liver injury.  
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3.4. Analysis of DEN-dependent effects on cell cycle activation 
and apoptosis in primary hepatocytes  
To further characterize the cellular role of DEN and CcnE1 on cell cycle 
control and apoptosis, it was aimed to establish a suitable in vitro cell culture model 
using cultured primary hepatocytes. For this approach, primary hepatocytes were 
isolated from WT and CcnE1-/- mice, stimulated with DEN to initiate cell damage and 
additionally treated with EGF and Insulin to induce proliferation. Using fluorescence-
activated cell sorting (FACS), DNA content per single cell was measured as a marker 
of cell cycle activity. Cell populations with DNA content <2n (subG1 population) 
indicated DNA degradation and were considered apoptotic cells.  
Interestingly, DEN stimulation alone did not affect cell death in either WT 
(17%) or CcnE1-/- primary hepatocytes (18%) compared to untreated controls (Figure 
3.19A). Cell cycle stimulation by adding EGF and Insulin after DEN-treatment clearly 
increased the subG1 population in CcnE1
-/- primary hepatocytes to 24% in 
comparison to only 15% in WT cells. However, overall DNA replication was not 
inhibited by either DEN or ablation of CcnE1 in this cell culture model (Figure 3.19A). 
Prolonged exposition to EGF and Insulin after DEN stimulation (48h) also increased 
apoptosis in primary WT hepatocytes. These data suggests that DEN triggers 
apoptosis in proliferating cells which is slightly accelerated in the absence of CcnE1. 
Unexpectedly, reliable measurements of cell cycle activity were not feasible with this 
cell culture model due to the nature of primary hepatocytes to perform several rounds 
of endoreplication (Guidotti et al., 2003). Therefore, at the end point of the 
experiment (24 h DEN; 48 h EGF/Insulin, Figure 3.19A, right panel) it could not be 
explicitly distinguished if CcnE1-/- hepatocytes are more prone to G2/M cell cycle 
arrest (lack of 2n population) or defective in endoreplication (lack of >8n population) 
as reported recently (Nevzorova et al., 2009). Thus, the applied in vitro model 
indicated an anti-apoptotic effect of CcnE1 in the DEN model but was otherwise of 
limited benefit.  
Changes in the DNA content of hepatocytes as shown in Figure 3.19A 
prompted the question if the polyploidization translated into an altered number of 
nuclei per cell. Counting nuclei per hepatocyte revealed a higher number of 
mononuclear primary hepatocytes in untreated controls compared to CcnE1-/- cells  
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Figure 3.19 Analysis of DEN-dependent effects on cell cycle activation and apoptosis in 
primary hepatocytes. Primary hepatocytes isolated from WT and CcnE1
-/-
 mice were cultured on 
collagen-coated plastic 6-well dishes and maintained in DMEM medium supplemented with 10% foetal 
bovine serum, penicillin and streptomycin. Primary hepatocyte culture was treated with 5 mM DEN 
with or without EGF (10 ng/ml) and Insulin (20 U/µl) as indicated and compared to untreated culture. 
(A) DNA content of cultured hepatocyte populations was determined by FACS. (B) The number of 
nuclei per WT and CcnE1
-/-
 primary hepatocyte, treated as indicated, is presented as histogram. Each 
bar represents a value of minimum 6 images; data are presented as the average percentage.  
(C) Untreated livers were collected from 6-8 weeks old male mice. Images of mouse liver H&E staining 
were investigated for difference in number of nuclei per hepatocyte between WT, CcnE1
-/-
 and  
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CcnE2
-/-
 animals. Binucleated hepatocytes are highlighted with dotted line. Scale bar: 20 µm. The 
number of binucleated and mononucleated hepatocytes in WT, CcnE1
-/-
 and CcnE2
-/-
 mice was 
presented in histogram as percentage of total hepatocyte number per high power field. ***: p<0.0005. 
 
(Figure 3.19B). Of notice, primary hepatocytes undergo spontaneous endomitosis in 
cell culture without any treatment as seen in untreated controls after 5 days. DEN 
alone did not induce any alteration, whereas treatment with EGF and insulin 
additionally increased a number of trinuclear and tetranuclear hepatocytes without 
significant differences between WT and CcnE1-/- cells. However, the observed 
difference in mononuclear primary hepatocytes remained constant throughout all 
conditions investigated, suggesting that CcnE1 is involved in control of endomitosis. 
This finding intrigued to determine if ablation of CcnE1 may alter the number of nuclei 
in vivo. Therefore, number of nuclei per hepatocyte was counted in H&E sections of 
untreated WT, CcnE1-/- and CcnE2-/- mice. Indeed, CcnE1-/- mice have a significantly 
reduced number of mononuclear hepatocytes (70 %) in comparison to WT (75 %) 
and CcnE2-/- (77 %) animals (Figure 3.19C). These results demonstrate that loss of 
CcnE1 affects endomitosis in favor of binucleated hepatocytes in vitro and in vivo. 
This could be of some relevance with respect to tumor susceptibility as binuclear 
hepatocytes might be less prone to malignant transformation due to the presence of 
redundant genetic material. However, this aspect was not further addressed in the 
present study. 
  
3.5. The cell cycle inhibitor p27 is negatively regulated by 
CcnE1 during early HCC progression.  
De-regulation of the cell cycle inhibitor p27 is found in various cancers 
including HCC (Matsuda, 2008). The previous experiments demonstrated that the 
p27 protein is constitutively expressed in healthy liver and further upregulated in 
CcnE1-/- mice upon acute challenge with DEN (compare Figure 3.13B). As CcnE1 
usually targets p27 for degradation, it was hypothesized that the tumor-suppressive 
effect in CcnE1-/- mice might be in part due to stabilized p27 protein in basically 
malignant transformed tissue.  To test if p27 also affects liver tumor progression 
under control of CcnE1, p27 western blot analyses were performed with liver 
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samples from WT, CcnE1-/- and CcnE2-/- mice with anticipated early tumor 
development (24 weeks after DEN treatment) or advanced tumor progression (40 
weeks post DEN). For each condition, five randomly selected liver samples were 
used and the p27 protein expression was quantified by measuring signal intensity 
relative to GAPDH expression using ImageJ software (Rasband, 1997-2011).  
As expected from earlier reports, several WT livers completely lacked p27 
protein already at early tumor development (Figure 3.20A, left panel) or during 
advanced tumor progression (Figure 3.20B, left panel). In contrast, the majority of 
CcnE1-/- livers showed marked p27 protein expression, whereas CcnE2-/- liver 
samples revealed an intermediate effect (Figure 3.20A-B, left panel). Quantification 
of these data revealed that overall p27 expression in CcnE1-/- mice is significantly 
higher during early tumor development (Figure 3.20A, right panel), whereas the 
observed differences did not reach statistical significance at advance tumor 
progression (Figure 3.20B, right panel). These data in combination with the previous 
results suggests that p27 is an important mediator of tumor suppression in CcnE1-/- 
mice due to increased stability.  
Cdk2 - in complex with E-type or A-type cyclins - is one of the main kinases 
involved in p27 phosphorylation at Thr187 thereby promoting cell cycle progression. 
Phosphorylation of p27 at both stages of tumor progression (early versus advanced) 
in WT, CcnE1-/- and CcnE2-/- liver was detected by immunohistochemical staining 
using a Thr187-specific antibody. Of notice, p27 phosphorylation was evident within 
defined dysplastic tissue areas in WT, CcnE1-/- and CcnE2-/- tissue, indicating that 
CcnE1 is not required for p27 phosphorylation (Figure 3.20C). However, CcnE1-/- 
livers were characterized by an overall lower amount of p-p27 positive cells with  
p-p27 localized predominantly in the cytoplasm, although precise quantification of 
these findings were not performed due to the heterogeneity of the investigated tissue 
sections (i.e. highly dysplastic in WT and mostly healthy in CcnE1-/-). Thus, CcnE1-
deficiency may trigger increased p27 stability through other mechanisms besides 
diminished phosphorylation.  
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Figure 3.20 CcnE1 is required for p27 inhibition in hepatocarcinogenesis. (A) Left panel: p27 
western blot analysis from DEN-treated WT, CcnE1
-/-
 and CcnE2
-/-
 livers 24 weeks after single DEN-
treatment (early tumor development). GAPDH expression was determined as equal loading control. 
Right panel: p27 western blot signal intensity was measured by ImageJ and compared to GAPDH 
band intensity. The ratio was calculated for each individual mouse and indicated as artificial pixel unit. 
(B) Left panel: p27 western blot analysis from DEN-treated WT, CcnE1
-/-
 and CcnE2
-/-
 livers 40 weeks 
after single DEN-treatment (advanced tumor progression). Right panel: Quantification of signal 
intensity as in (A). (C) Phosphorylation of p27 on Thr187 in liver tumor samples was determined by 
immunohistochemistry of paraffin embedded sections. P-p27 positive liver cells are stained in brown 
and are highlighted by arrows. Scale bar: 50 µm. 
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3.6. The oncogenic potential of CcnE1 in the liver depends on 
functional Cdk2 in hepatocytes  
The canonical cell cycle activation in mammals involves physical interaction of 
CcnE1 or CcnE2 with Cdk2 thereby forming a functional kinase, which then 
phosphorylates and subsequent activates substrates driving the initiation of DNA 
synthesis (Caldon and Musgrove, 2010). However, as described before (compare 
chapter 3.1) genetic inactivation of Cdk2 or of a single E-Type cyclin does not affect 
cell proliferation during embryonic development or liver regeneration (Geng et al., 
2001; Kaldis and Aleem, 2005; Nevzorova et al., 2009; Ortega et al., 2003), pointing 
to a non-canonical, Cdk2-independent function of CcnE and overlapping roles of 
CcnE1 and CcnE2. In line with this hypothesis, a recent study described a Cdk2-
independent function of CcnE1 for the formation of the pre-replication complex and 
origin firing (Geng et al., 2007). 
In order to distinguish if the tumor-promoting activity of CcnE1 in the DEN 
model is Cdk2-dependent or the result of a non-canonical CcnE1-function, 
conditional knockout mice with hepatocyte-specific deletion of Cdk2 were generated. 
For this approach, mice carrying loxP recombination sites in intron 1 and 3 of the 
Cdk2 gene (Cdk2f/f, (Ortega et al., 2003) were kindly provided by Dr. M. Barbacid 
(CNIO, Madrid, Spain) and crossed with transgenic mice expressing the cre-
recombinase under the control of the hepatocyte-specific albumin promoter 
(Kellendonk et al., 2000). Efficient hepatic Cdk2 inactivation in these Cdk2Δhepa mice 
was confirmed by rt-PCR using specific primers for exon 1 and 4 respectively (Figure 
3.21A). 
Analogous to previous experiments, Cdk2Δhepa mice and Cdk2f/f animals 
(referred to as wild type controls) were first characterized after high-dose DEN-
induced acute liver injury. Determination of ALT serum transaminase levels (Figure 
3.21B) and histological analysis of H&E stained liver sections (Figure 3.21C) 
revealed a similar degree of strong liver injury in both groups. Liver apoptosis was 
determined by TUNEL staining and measurement of caspase-3 activity 0-72 h after 
DEN treatment (Figure 3.21D-E) revealing no significant effect of the Cdk2 
inactivation on hepatocyte survival after DEN treatment. Thus, DEN induced the 
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same liver damage and comparable cell death response in Cdk2Δhepa mice and 
controls. 
 
Figure 3.21 Cdk2 specific hepatocyte loss does not alter apoptosis or proliferation in DEN-
induced liver injury. (A) Cdk2 deletion efficiency was measured by PCR with specific primers in 
exon1 and exon4 and with whole liver cDNA. Wildtype band (Cdk2
f/f
) is 465 base pairs (bp) in size and 
product without exons 2 and 3 (Cdk2
Δhepa
) is approximately 250 bp. (B-E) 6-8 weeks old Cdk2
f/f
 and 
Cdk2
Δhepa
 mice were injected with DEN (200 mg/kg i.p.) to induce acute liver injury; livers were 
investigated up to 96 hours after injection. (B) Serum level of alanine-aminotransferase (ALT) of mice 
at indicated time points after DEN injection. Each bar represents a value of minimum 3 animals, data 
are presented as the average ± s.d. (C) H&E staining of paraffin embedded liver sections 48 hours 
after DEN. Scale bar: 100 µm. (D) TUNEL staining on frozen liver sections 48 hours after DEN, 
TUNEL positive cells are green, nuclei are visualized by DAPI: blue. Scale bar: 50 µm. (E) Caspase-3 
activity was measured by assay for specific caspase-3 substrate turnover and calculated as fold 
induction in comparison to untreated livers for Cdk2
Δhepa
 (squares) and Cdk2
f/f
  (circles) animals. Each 
value represents a minimum of 3 animals, data are presented as the average ± s.d.  
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To test, if hepatocarcinogenesis in the DEN model depends on a functional 
CcnE1/Cdk2 complex, 2 weeks old Cdk2f/f and Cdk2Δhepa mice were injected with 
DEN to induce HCC and analyzed 38 weeks after treatment in agreement with the 
previous experiments. As expected, 100 % of Cdk2f/f mice (8/8) developed liver 
tumors with an average of 38 tumors per mouse and a mean tumor diameter of 8 mm 
(SD ± 4 mm, Figure 3.22A, left panel and Figure 3.22B-C). In contrast, hepatocyte-
specific deletion of Cdk2 resulted in reduced tumor incidence of 90% (7/8). More 
interestingly, tumor frequency and tumor growth in Cdk2Δhepa mice were strongly 
decreased showing an average of 6 liver tumors per mouse and a mean tumor 
diameter of only 3mm ± 1 mm (Figure 3.22A, middle panel and Figure 3.22B-C). In 
agreement with strongly decreased tumor burden in DEN-treated Cdk2Δhepa mice, the 
liver mass index in these animals at the age of 40 weeks was normal (approximately 
5 %) and comparable to healthy and untreated mice, whereas Cdk2f/f mice showed 
significantly increased liver mass index (9% SD: ± 3%,  Figure 3.22D) due to strong 
tumor load. Therefore, Cdk2Δhepa mice are similarly protected from DEN-mediated 
hepatocarcinogenesis as shown before in CcnE1-/- mice. These data suggests that 
HCC-development depends on both functional CcnE1 and Cdk2 in hepatocytes. 
Cdk2Δhepa animals still express CcnE1 and CcnE2 and the previous data 
suggested that CcnE1 is a key cyclin for hepatocarcinogenesis. To further rule out 
that CcnE1 may perform non-canonical functions during tumor development, double 
mutants with a constitutive knockout of CcnE2 and conditional ablation of Cdk2 
(Cdk2ΔhepaCcnE2-/- mice) were generated and subjected to single low-dose DEN 
treatment for HCC induction. Interestingly, Cdk2ΔhepaCcnE2-/- mice revealed similar 
protection from tumor formation and tumor growth as found in Cdk2Δhepa mice, with 
an average of 6 liver tumors per mouse and a mean diameter of 3mm (SD:± 1 mm, 
Figure 3.22A, right panel and Figure 3.22B-C).  
Previous experiments demonstrated increased CcnE1 expression in DEN-
induced tumors derived from WT or CcnE2-/- mice (compare Figure 3.6A). Similarly, 
CcnE1 mRNA expression was highly (approximately 10fold), but not significantly 
different induced in livers from DEN-treated Cdk2f/f, Cdk2Δhepa and Cdk2ΔhepaCcnE2-/- 
mice (Figure 3.22E). Therefore, hepatic tumor formation depends not only on CcnE1 
induction but also requires availability of the canonical binding partner Cdk2. 
However, CcnE1 gene induction seems to be independent of Cdk2. Interestingly, 
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DEN-treatment did not induce CcnE2 mRNA expression in Cdk2Δhepa mice (Figure 
3.22E, medium panel).  
 
 
Figure 3.22 Cdk2 is required for hepatocarcinogenesis induced by DEN. Cdk2
f/f
 (n=8), Cdk2
Δhepa
 
(n=8) and Cdk2
Δhepa
CcnE2
-/-
 (n=6) male mice at the age of 14 days were treated once with DEN 
(25mg/kg i.p.). At the age of 40 weeks, animals were sacrificed and analysed for markers of 
hepatocellular carcinoma. (A) Macroscopic appearance of representative 40 week old livers and 
tumors derived from Cdk2
f/f
, Cdk2
Δhepa
 and Cdk2
Δhepa
CcnE2
-/-
 animals. (B) Number of visible tumors for 
each individual mouse is determined. (C) For each individual mouse the size of the largest tumor is 
given as an indicator for tumor growth. (D) Liver/body weight ratio in DEN-treated mice at the age of 
40 weeks. *: p<0.05. (E) mRNA expression of indicated genes was measured by real-time PCR 
analysis in 40 week liver tissue for Cdk2
f/f
 (white bars), Cdk2
Δheap
 (grey bars) and Cdk2
Δhepa
CcnE2
-/-
 
(black bars) animals treated as described. Expression levels were normalized to expression of the 
housekeeping gene GAPDH and calculated as fold induction in comparison to untreated controls. 
Each bar represents a value of minimum 6 animals, data are presented as the average ± s.d. *: 
p<0.05; **: p<0.005.  
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As previously demonstrated (Figure 3.6C), CcnE1 was required for driving 
CcnA2 expression and DNA replication during advanced tumor progression in the 
liver. This gene regulation of CcnA2 is also dependent on functional Cdk2. 
Accordingly, CcnA2 mRNA expression was only detectable at baseline levels in aged 
livers from DEN-treated Cdk2Δhepa and Cdk2ΔhepaCcnE2-/- mice in contrast to control 
mice with CcnA2 upregulation and strong tumor load (Figure 3.22E, right panel). 
These findings hint at an essential role of the CcnE1/Cdk2 complex for S-phase 
initiation and CcnA2 expression specifically during tumor progression. 
In summary, CcnE1 essentially promotes liver carcinogenesis in cooperation 
with its canonical binding partner Cdk2, which cannot be compensated by closely 
related homologues such as CcnE2 or alternative Cdks.  
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4. Discussion 
The main objective of this work was to examine the contribution of E-type 
cyclins in cancer development and progression. To address this question, the 
previously described CcnE1 and CcnE2 knockout mice were further characterized in 
DEN-induced liver cancerogenesis. Interestingly, the loss of CcnE1 leads to an 
impressive inhibition of chemically induced liver cancer. This approach further 
demonstrated that CcnE1 deficiency alters both tumor initiation and progression in 
mice, as depicted by a strong reduction in tumor number and tumor size. This finding 
suggests that CcnE1 and CcnE2 have very distinctive roles in tumorigenesis. 
Employing a model of acute liver injury in order to mimic early events of tumor 
development revealed that CcnE1 represses cell cycle arrest and attenuates the 
DNA damage-induced checkpoint control after genotoxic stress. Additionally, to 
determine whether the function of CcnE1 in tumorigenesis is a Cdk2-dependent 
effect, Cdk2Δhepa and Cdk2ΔhepaCcnE2-/- mice were generated and subjected to DEN 
treatment. CcnE1 alone in these mice was not able to severely induce and promote 
DEN-induced cancerogenesis. Thus, this study indicates that targeting CcnE1 in 
hepatocellular carcinoma to be a potential therapeutic approach. 
 
4.1. Distinct roles of CcnE1 and CcnE2 in 
hepatocarcinogenesis 
The roles of CcnE1 and CcnE2 were postulated to be redundant based on 
high sequence homology, and furthermore redundancies with CcnA2 have also been 
suggested based on findings that CcnA2-Cdk2 activity can substitute for CcnE-Cdk2 
(Caldon and Musgrove, 2010; Kaldis and Aleem, 2005; Nevzorova et al., 2009). 
Animal knockout models have revealed that deletion of either CcnE1 or CcnE2 
results in primarily normal phenotypes; however, the importance of CcnE was 
emphasized by the fact that CcnE1-/-CcnE2-/- double knockout mice are embryonic 
lethal (Geng et al., 2003; Parisi et al., 2003). CcnE1-/- and CcnE2-/- mice have only 
slight differences in the velocity of regenerative response, as previously investigated 
in a liver regeneration model (Nevzorova et al., 2009). Based on the results from 
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these studies, it was not expected that the loss of CcnE1 would have a striking 
impact on chemically induced hepatocellular carcinoma. Experiments with small 
interfering RNA (siRNA) targeting CcnE1 in human HCC cell lines, as well as in other 
cell lines, hinted toward increased sensitivity for arrest and apoptosis, although the 
role of CcnE2 in this setting was not analyzed (Li et al., 2003; Liang et al., 2010; 
Todd et al., 2009). However, recent studies targeting either CcnE1 or CcnE2 with 
siRNA showed comparable results in reducing the proliferative potential of cancer 
cell lines, again indicating to overlapping functions of CcnE1 and CcnE2 (Caldon and 
Musgrove, 2010; Dapas et al., 2009). In the present study, it was clearly shown that 
CcnE1 - but not CcnE2 - is an important oncogene in liver tumor development 
following carcinogen insult and its expression is likely necessary for the ability of the 
transformed cell to proliferate.  
In addition to the effect of CcnE1 deficiency on tumor initiation and 
progression, its expression is apparently critical for the induction of CcnE2 and 
CcnA2 during tumorigenesis as CcnE1 knockout mice exposed to DEN treatment 
express much lower levels of CcnE2 and CcnA2 than WT animals. This correlates 
with results from a previous study showing a physical interaction between CcnE and 
the CcnA2 promoter leading to activation of transcription (Schulze et al., 1995; 
Zerfass-Thome et al., 1997). Moreover, it is likely that generally low cyclin expression 
levels considerably contribute to tumor inhibition. It is interesting to note that the low 
CcnE2 and CcnA2 expression levels found in CcnE1 knockout mice is likely specific 
for transformed cells; which is in strong contrast to the liver regeneration model 
where CcnA2 is highly induced and replaces CcnE1 and/or CcnE2 (Nevzorova et al., 
2009). In this work it was demonstrated that transformed CcnE1-deficient cells during 
tumor development cease to proliferate and to some extent undergo senescence, 
therefore highlighting the differential and nonredundant roles of CcnE1 and CcnE2.  
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4.2. New signaling pathways involved during CcnE1-driven 
carcinogenesis 
The model used in this study has been previously developed and established 
in order to expose the initial events involved in liver cell transformation following a 
genotoxic hit such as DEN (Maeda et al., 2005). An aim of this study was to 
determine if the loss of CcnE1, following acute liver injury, impacts critical elements 
of cellular signaling cascades that are necessary for transformation and tumor 
development. Surprisingly, although others have suggested that cell death is one of 
the decisive mechanisms deciding pro or contra tumorigenesis, no clear differences 
were evident in apoptosis induction in our study (Eferl et al., 2003; Maeda et al., 
2005). Interesting, however, was the reduction in F4/80 positive Kupffer cells, the 
resident liver macrophage, in CcnE1-deficient mice after DEN treatment suggesting 
an important role for CcnE1 in their regulation following insult. This result further 
supports the finding that superoxide produced by Kupffer cells during liver damage 
and inflammation contributes to hepatocarcinogenesis by aggravating genotoxic and 
cytotoxic effects in hepatocytes (Teufelhofer et al., 2005). Taking these results 
together it is suggested that the temporary loss of Kupffer cells at the time of maximal 
tissue and cell damage presumably improves the outcome in tumorigenesis.  
One mechanism by which CcnE1 might promote tumor formation is by 
antagonizing an arrest of transformed and/or damaged cells. Cell cycle arrest is 
critical in order for DNA repair to occur and the mediators regulating cell cycle 
progression are known as CDK inhibitors. DEN-treated CcnE1-deficient liver cells 
undergo arrest that is associated with elevated levels of the prominent tumor 
suppressors p21 and p27. In case of p27, this finding persists till later time points in 
tumor development, and tumors of CcnE1-deficient DEN-treated mice display 
aberrantly elevated levels of p27. Absence or cytoplasmic localization of p21 or p27 
within solid tumor is recognized as an indicator of poor prognosis in patients 
(Abukhdeir and Park, 2008), and consequently, the finding that p27 is less 
phosphorylated (thus inactivated) in CcnE1-deficient tumors confirmed the 
importance of p27 in reducing tumor cell proliferation.  
DNA damage checkpoint activation after genotoxic stress is the primary barrier 
to tumorigenesis. There are two pathways that should protect cells against excessive 
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CcnE activity. The first is a p53-dependent response that suppresses CcnE kinase 
activity through induction of the inhibitor p21, and the second is the pathway of CcnE 
degradation (Minella et al., 2007). p53 is a hallmark tumor suppressor which induces 
cell cycle arrest and/or apoptosis in response to DNA damage; its levels are 
commonly decreased in tumors. Phosphorylation of p53 on either Ser15 or Ser20 is 
an important modification that prevents Mdm2 binding and thus inhibits Mdm2-
dependent degradation (Meek and Anderson, 2009). The CcnE1-deficient animals 
displayed stronger and prolonged p53 stabilization after DEN treatment suggesting 
that CcnE1 is interfering with p53-dependent checkpoint activity.  
c-Jun N-terminal kinases (JNKs) are responsive to stress stimuli and play 
important roles in cell growth, survival and apoptosis. Analysis of the JNK pathway in 
CcnE1 deficient DEN-treated animals revealed an up-regulation. Substrates for JNK 
activity also include p53, and depending on the cellular context JNK either 
destabilizes p53 by binding to it or stabilizes p53 by phosphorylation thereby 
inhibiting ubiquitin-mediated degradation (Fuchs et al., 1998a; Fuchs et al., 1998b). 
Thus, the drop in JNK and p53 activity observed in the DEN-treated animals with 
functional CcnE1 may be the cause of dyssregulated checkpoint, whereas loss of 
CcnE1 probably supports checkpoint activity and adequate repair. How CcnE1 
exactly interferes with p53 stabilization and JNK activation still has to be identified.  
 During late stages of tumor progression the loss of CcnE1 is associated with 
enhanced senescence. For this reason senescence was also assessed in DEN-
induced acute liver injury model. Unexpectedly, CcnE2 treated animals displayed 
high amounts of SA β-galactosidase activity, a well-established marker of 
senescence. Bartkova et al reported oncogene-induced senescence in cells with 
ectopic CcnE1 overexpression in response to replication stress. However, in that 
study, only retrovirus infected cell lines were tested. In contrast to this study, many 
human cancers with CcnE1 overexpression and/or amplification show elevated 
proliferation rather than signs of senescence. Taken together the current results as 
well as those from previous reports suggest that overexpression of CcnE1 in CcnE2 
deficient animals during acute liver injury may be beyond “usual” levels found in 
tumors and thus drives cells into senescence. Furthermore, these mice also display 
exceptionally high levels of IL-6, which might support the described phenomenon of 
senescence-associated secretory phenotype (SASP), which occurs after 
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establishment of persistent DNA damage signaling (Rodier et al., 2009). This 
observation was not examined in detail in the present study but deserves further 
investigation. 
Why does the discrepancy arise between senescence induction in the acute 
liver injury model as compared to mice with established tumors even when the same 
chemical is applied? One possible explanation is the different age conditions. Tumor 
induction is initiated by injecting 14-day old neonatal mice with DEN (25 mg/kg), 
while the animals are still developing and therefore DEN induced mutations become 
prominent through liver growth. The mice used in the acute liver injury model are 
adult (6-8 week old) and as the liver cells have reached quiescence, an 8-fold higher 
DEN dose was necessary to induce tissue damage and regeneration. To obtain 
direct insight into the immediate response of DEN relevant for tumor induction, 
neonatal mice were sacrificed 48 hours after injection. WT mice revealed very low 
levels of apoptosis, which was slightly augmented in CcnE1-deficient animals. CcnE1 
deficiency resulted in obvious cell cycle arrest in comparison to WT animals as 
ascertained by PCNA immunostaining, whereas pH2AX staining, an indicator of DNA 
double strand brakes, showed comparable DEN-induced DNA damage between the 
genotypes as observed in the acute liver injury model. These experiments 
demonstrated that DEN-induced acute liver injury is an efficient tool to investigate 
early events in tumor development. However, the limitations in the adult mouse 
model are increased tissue damage and manifestation of senescence that were not 
present in neonatal mice. Nevertheless, in this work, new signaling pathways 
following DEN-induced DNA damage were identified in the DEN-induced acute liver 
injury model.  
The results from the regeneration model with CcnE1 and CcnE2 knockout 
mice showed normal proliferation of liver cells due to the largely overlapping 
functions of these two proteins (Nevzorova et al., 2009). In contrast, the present work 
identifies a unique role for CcnE1 depending on the environmental milieu (toxic 
injury) and further emphasizes its role in cancerogenesis.   
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Figure 4.1 Proposed CcnE1-Cdk2 function in non-toxic and genotoxic injury. CcnE1-Cdk2 
seems to be dispensable for proliferation following non-toxic injury such as partial hepatectomy; 
however, functional CcnE1-Cdk2 complex is required for tumor development after genotoxic injury e.g. 
DEN. 
The DEN model places CcnE1 into genotoxic damage scenery and highlights 
its important role in tumor initiation and development. Studies with other genotoxic 
agents, such as carbon tetrachloride (CCl4) support this notion with the finding that 
CcnE1 plays an important role in CCl4-induced liver fibrosis (Nevzorova et al. 
unpublished data). Finally, these results support the hypothesis that CcnE1 function 
is different under genotoxic or non-genotoxic stress conditions (Figure 4.1). 
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4.3. Oncogene CcnE1 function is Cdk2 dependent  
The present work demonstrated that CcnE1 is one of the key genes driving 
chemically induced hepatocarcinogenesis; however an open question remained as to 
whether CcnE1 can operate without its canonical interaction partner Cdk2 in tumor 
development. Usually CcnE1 functions as a regulatory subunit of Cdk2 which is 
essential for G1 to S-phase transition and DNA replication. However, CcnE1 has also 
been described to contain kinase-independent functions, involving the loading of 
minichromosome maintenance (MCM) proteins onto the replication origin (Geng et 
al., 2007). Very recently, two studies revealed that Cdk2-deficient mice are 
completely resistant to oncogene ErbB2 and LMW-CcnE mediated mammary tumors 
(Akli et al., 2011; Ray et al., 2011). This study has clearly shown that Cdk2 is an 
important component of an oncogenic complex involved in liver cancer, as 
exemplified by Cdk2 hepatocyte deficient animals, which display massive reduction 
of tumor development upon carcinogen treatment. It was also suggested that CcnE2 
might control CcnE1 expression (Nevzorova et al., 2009), and in light of this theory, 
double knockout mice Cdk2ΔhepaE2-/- were generated and treated with DEN to test 
whether CcnE1 alone can drive tumorigenesis. Nevertheless, these mice displayed 
the same resistance to DEN-induced liver tumors as single hepatocyte Cdk2-
deficient animals. This observation suggests that liver cancers with CcnE1 
upregulation should be considered for Cdk2 inhibitor therapy clinical trials.  
Traditionally, the diagnosis of HCC was not possible before the advanced 
stage of disease. However in the last few years in many patients HCC was 
diagnosed at an early stage due to improved imaging techniques when liver function 
can still be preserved. Treatments usually used are surgical resection, 
transplantation and percutanous ablation (Llovet et al., 2003). Molecular targeted 
therapy of HCC showed encouraging results in case of Sorafenib, a multikinase 
inhibitor (Llovet et al., 2008). CcnE1 overexpression has been demonstrated in many 
cancers, including HCC, and this study confirmed that inhibition of CcnE1 is 
promising new treatment modality for HCC. Up to date, no specific chemical inhibitors 
for CcnE1 have been developed, although diverse Cdk inhibitors with broad target 
specificity exist. Roscovitine (Seliciclib) and related compounds could be very 
promising for HCC treatment, showing a higher degree of selectivity.  
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4.4. Future impacts and directions 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and 
is among one of the leading causes of cancers worldwide associated with high 
mortality (Parkin, 1998). Identification of new signaling pathways and specific 
molecules regulating cancerogenesis is critical for development of new drug 
therapies. Perturbed cell cycle signaling is one of the important events leading to 
cancer (Villanueva and Llovet). This study showing the importance of CcnE1 and 
Cdk2 provides a new window for specific targeting of liver cancers. Future treatments 
of HCC, potentially with Cdk2-specific inhibitors such as Roscovitine, might benefit of 
patient stratification based on CcnE1 expression status. Existing Cdk inhibitors are 
not specific to only one Cdk and inhibiting Cdk2 might interfere with DNA repair. 
Based on this data, it would be recommendable to inhibit CcnE1 specifically, 
considering that ubiquitous loss of CcnE1 has no negative effect. Finally, continuing 
to elucidate the role of CcnE1 in cancer will hopefully lead to the development of 
CcnE1-specific inhibitors for cancer treatment.  
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5. Summary 
E-type cyclins (CcnE) control the transition of quiescent cells into the cell 
cycle. Two E-type cyclins, CcnE1 and CcnE2 have been described. A variety of 
human cancers, including hepatocellular carcinoma (HCC), overexpress CcnE and 
this is frequently associated with reduced patient survival. The aim of the present 
study was to dissect the role of CcnE1 and CcnE2 for hepatocarcinogenesis induced 
by the carcinogen diethylnitrosamine (DEN) using CcnE1 and CcnE2 knockout mice. 
The central question was how the genetic loss of CcnE1 or CcnE2 would affect tumor 
initiation and/or progression.  
The study revealed several unexpected findings. CcnE2-/- mice developed liver 
tumors of similar number and size compared to wild type (WT) animals 
demonstrating for the first time that CcnE2 is dispensable for development of liver 
cancer. Surprisingly, CcnE1-deficient animals were mostly resistant to HCC induction 
and showed poor tumor growth. Therefore the present data suggests that CcnE1- but 
not its homologue CcnE2 - is essential for initiation and progression of liver cancer.  
The molecular mechanisms underlying these findings were further investigated 
in a model of DEN-induced acute liver injury, which reflected immediate early events 
of cell transformation and cellular signaling. DEN-mediated liver injury was genotoxic 
and triggered a DNA damage response pathway (DDR) and activation of Jun kinases 
(JNK) already 24 and 48 hours after treatment in all genotypes. Interestingly, CcnE1-
deficient livers revealed transient hyper-activation of JNK and more importantly a 
stronger and prolonged expression of the tumor suppressor p53. In good agreement, 
CcnE1-/- livers showed also prolonged cell cycle arrest associated with increased 
expression of cell cycle inhibitors p21 and p27 following DEN challenge. Thus 
expression of CcnE1 was shown to be essential to overcome the cell cycle arrest and 
DDR of hepatocytes immediately after mutagenic treatment.  
In another approach knockout mice with a hepatocyte-specific deletion of 
Cdk2 (Cdk2Δhepa) and Cdk2Δhepa CcnE2-/- double knockout mice were generated and 
subjected to DEN treatment. Importantly, these strains were also strongly protected 
from HCC formation similar to CcnE1-/- mice.  
In summary, the present study demonstrated for the first time that CcnE1 is an 
essential oncogene in the liver and drives hepatocarcinogenesis and tumor growth in 
a Cdk2-dependent manner. 
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6. Zusammenfassung 
E-Cycline (CcnE1 und CcnE2) kontrollieren den Übergang von ruhenden 
Zellen in den Zellzyklus. In vielen humanen Tumoren inklusive des hepatozellulären 
Karzinoms (HCC) sind E-Cycline überexprimiert, was mit einem verminderten 
Patientenüberleben assoziiert ist. Ziel der vorliegenden Arbeit war die funktionelle 
Charakterisierung von CcnE1 und CcnE2 bei der Leberkrebsentstehung in einem 
Modell der chemisch induzierten Hepatokarzinogenese durch Diethylnitrosamin 
(DEN) unter Verwendung von CcnE1- und CcnE2 knockout Mäusen. Zentrale Frage 
der Arbeit war, inwieweit die genetische Inaktivierung von CcnE1 oder CcnE2 die 
Tumorentstehung oder das Tumorwachstum beeinflusst.  
Die vorliegende Arbeit zeigt mehrere unerwartete Ergebnisse: CcnE2-/- Mäuse 
und Wildtyp (WT) Kontrolltiere bildeten Lebertumore in gleicher Zahl und Größe. 
Diese Daten beweisen erstmals, dass CcnE2 für die Tumorentstehung in der Leber 
nicht benötigt wird. Überraschender Weise waren CcnE1-/- Mäuse weitestgehend 
resistent gegen die DEN-vermittelte HCC-Entstehung und Tumorwachstum. Dies 
zeigte, dass CcnE1 – nicht aber sein Homologes CcnE2 – für Tumorentstehung und 
Wachstum in der Leber essentiell ist. Zur Charakterisierung von unmittelbaren, 
frühen Ereignissen in der Zelltransformation und der zellulären Signaltransduktion 
wurde das Modell der DEN-induzierten akuten Leberschädigung verwendet. In allen 
drei Genotypen induzierte DEN bereits 24-48 h nach Stimulation eine DNA-
Schädigungsantwort und Aktivierung von JUN-Kinasen (JNK). Interessanter Weise 
zeigte sich in CcnE1-defizienten Lebern eine stärkere Aktivierung von JNK sowie 
eine verlängerte und stärkere Expression des Tumorsuppressors p53. In Über-
einstimmung mit diesem Befund zeigten diese Mäuse auch einen verlängerten 
Zellzyklusarrest, der mit einer erhöhten Expression der Zellzyklusinhibitoren p21 und 
p27 einherging. Expression von CcnE1 nach mutagener Leberschädigung führt also 
zu einer Überwindung des Zellzyklusarrest. In einem weiteren Ansatz wurden 
hepatozyten-spezifische Cdk2 knockout Mäuse (Cdk2Δhepa) und Cdk2ΔhepaCcnE2-/- 
doppelknockout Mäuse generiert und mit DEN behandelt, und beide Mauslinien 
waren ähnlich wie CcnE1-/- Tiere vor Entstehung eines HCC geschützt.  
Zusammenfassend beweist die vorliegende Arbeit erstmalig, dass CcnE1 in 
Kooperation mit seiner assoziierten Kinase Cdk2 ein essentielles Leber-Onkogen 
darstellt. 
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8. Appendix 
8.1 Abbreviations 
A Ampere 
aa Amino acid 
ALT Alanine-aminotransferase 
AP Apurinic/apirimidinic 
APC/C Anaphase promoting complex / cyclosome 
APS Ammoniumperoxodisulfat 
ARP Aldehyde reactive probe 
AST Aspartate-aminotransferase 
ATP Adenosintrisphosphat 
ATM Ataxia-telangiectasia mutated protein kinase 
ATR ATM + Rad3-related protein kinase 
bp Base pair 
BSA Bovine Serum Albumin 
Bq Becquerel 
CAK Cdk-activating kinase 
Cat Catalase 
CcnA Cyclin A 
CcnD Cyclin D 
CcnE Cyclin E 
Cdk Cyclin dependent kinase 
cDNA Complementary DNA 
°C Degree Celsius  
Cip Cdk interacting protein 
CKI Cyclin dependent kinase inhibitor 
CLS Centrosome localization signal 
CTD C-terminal domain 
2D two dimension 
2D-DiGE 2D in-Gel electrophoresis 
Da Dalton 
DAB 3,3´-diamino benzidine 
DAPI 4,6-diamino-2-phenylindole 
DDR DNA damage response 
DEN diethylnitrosamine 
DMEM Dulbecco´s modified Eagle´s medium 
DNA Desoxyribonucleic acid 
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dNTP Desoxyribonukleotidtrisphospate 
DTT Dithiothreitol 
EDTA Ethylendiamintetraacetic acid 
ECL Enhanced chemiluminescence 
EGF Epidermal growth factor 
FACS Fluorescence activated cell sorting 
Fb Fibronectin 
Fbw7 F-box and WD repeat domain-containing 7 
FCS Fetal calf serum 
FITC Fluoresceinisothocyanat 
g gram 
g gravity 
G6P Glucose-6-phosphatase 
Gadd45 Growth arrest and DNA damage 45 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
h hour 
H&E Hematoxylin and eosin 
HCC Hepatocellular carcinoma 
HRP Horseradish peroxydase 
IF Immunofluorescence 
IHC Immunohistochemistry 
IL interleukine 
JNK c-Jun N-terminal kinase 
k kilo 
kb kilo base 
Kip kinase inhibitory protein 
L liter 
LMW Low molecular weight 
µ- micro (10-6) 
m- mili (10-3) 
m Meter 
M Molar 
MCM Minichromosome maintenance 
Mdm2 Murine double minute 2 
min Minute 
MnSOD Manganese superoxide dismutase 
MOPS Morpholinopropansulfon 
mRNA Messenger RNA 
NAFLD Nonalcoholic fatty liver disease 
NASH Nonalcoholic steatohepatitis 
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NLS Nuclear localization signal 
NSLC non-small-cell lung carcinoma 
O6-EtdG O6-ethyldeoxyguanosine 
O4-EtdT O4-ethyldeoxythymidine 
OD Optical density 
PBS Phosphate buffered saline 
PBST PBS-Tween 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PEST prolin (P), Glutamic acid (E), Serine (S), Threonine (T) 
PFA Paraformaldehyde 
PH Partial hepatectomy 
PI Propidium iodide 
ppb Parts per bilion 
Rb Retinoblastoma 
RNA Ribonucleic acid 
rpm Rotations per Minute 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
s second 
SA-β-gal Senescence associated β-galactosidase 
SCF Skp1-cullin-F-box-Komplex 
s.d. Standard deviation 
SDS Sodium dodecyl sulphate 
Ser Serine 
siRNA Small interference RNA 
Skp S-phase kinase associated protein 
Tab. Table 
TAE Tris Acetate EDTA Buffer 
TAK/P-TEFb CyclinT1/P-TEFb 
P-TEFb Positive transcription elongation factor b 
TBE Tris Borate EDTA Buffer 
TBS Tris buffered saline 
TE Tris-EDTA-Buffer 
TEMED N´,N,N´,N´-Tetramethyldiamine 
TFIIH Transcription factor II H 
TGF-beta Transforming growth factor beta 
Thr Threonine 
Tris 2-Amino-2(hydroxymethyl)-1,3-propandiol 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
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Tween 20 Polyoxyethylensorbitanmonolaureat 
UV ultraviolet 
V Volt 
v/v Volume per Volume 
VXCXE Valine (V), unspecified (X), Cysteine (C), X, Glutamic acid (E) 
WT Wild type 
w/v Weight per Volume 
X-Gal 5-Bromo-4-Chloro-3-indolyl β-D-Galactopyranoside 
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